{
 "documentInfo": {
  "documentType": "https://xbrl.org/2021/xbrl-json",
  "features": {
   "xbrl:canonicalValues": true
  },
  "namespaces": {
   "ifrs-full": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
   "iso4217": "http://www.xbrl.org/2003/iso4217",
   "scheme": "http://standards.iso.org/iso/17442",
   "targethealthcare": "http://targethealthcare.com/xbrl/2023",
   "xbrl": "https://xbrl.org/2021",
   "xbrli": "http://www.xbrl.org/2003/instance"
  },
  "taxonomy": [
   "http://targethealthcare.com/xbrl/2023/targethealthcare-2023-06-30.xsd"
  ]
 },
 "facts": {
  "fact-1": {
   "value": "UK",
   "dimensions": {
    "concept": "ifrs-full:DomicileOfEntity",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-2": {
   "value": "Public Limited Company",
   "dimensions": {
    "concept": "ifrs-full:LegalFormOfEntity",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-3": {
   "value": "Th<span class=\"_ _2\"></span>e Gro<span class=\"_ _2\"></span>up ca<span class=\"_ _2\"></span>rri<span class=\"_ _2\"></span>es o<span class=\"_ _2\"></span>n busi<span class=\"_ _2\"></span>ne<span class=\"_ _2\"></span>ss as a Rea<span class=\"_ _2\"></span>l Es<span class=\"_ _2\"></span>tate In<span class=\"_ _2\"></span>vest<span class=\"_ _2\"></span>me<span class=\"_ _2\"></span>nt T<span class=\"_ _1\"></span>rust a<span class=\"_ _2\"></span>nd h<span class=\"_ _2\"></span>as be<span class=\"_ _2\"></span>en a<span class=\"_ _2\"></span>pprove<span class=\"_ _2\"></span>d as su<span class=\"_ _2\"></span>ch by HM Reve<span class=\"_ _2\"></span>nue &amp; Cu<span class=\"_ _2\"></span>stom<span class=\"_ _2\"></span>s (\u2018<span class=\"_ _2\"></span>HMRC<span class=\"_ _2\"></span>\u2019<span class=\"_ _2\"></span>), subj<span class=\"_ _2\"></span>ec<span class=\"_ _2\"></span>t to it conti<span class=\"_ _2\"></span>nui<span class=\"_ _2\"></span>ng to me<span class=\"_ _2\"></span>et the re<span class=\"_ _2\"></span>leva<span class=\"_ _2\"></span>nt el<span class=\"_ _2\"></span>igi<span class=\"_ _2\"></span>bil<span class=\"_ _2\"></span>it<span class=\"_ _2\"></span>y cond<span class=\"_ _2\"></span>itio<span class=\"_ _2\"></span>ns an<span class=\"_ _2\"></span>d on<span class=\"_ _2\"></span>go<span class=\"_ _2\"></span>ing re<span class=\"_ _2\"></span>qui<span class=\"_ _2\"></span>reme<span class=\"_ _2\"></span>nt<span class=\"_ _2\"></span>s. A<span class=\"_ _2\"></span>s a resu<span class=\"_ _2\"></span>lt, t<span class=\"_ _2\"></span>he p<span class=\"_ _2\"></span>rofit<span class=\"_ _2\"></span>s of th<span class=\"_ _2\"></span>e Gro<span class=\"_ _2\"></span>up\u2019s prop<span class=\"_ _2\"></span>er<span class=\"_ _2\"></span>t<span class=\"_ _2\"></span>y re<span class=\"_ _2\"></span>ntal<span class=\"_ _2\"></span> bus<span class=\"_ _2\"></span>ine<span class=\"_ _2\"></span>ss<span class=\"_ _2\"></span>, comp<span class=\"_ _2\"></span>risi<span class=\"_ _2\"></span>ng b<span class=\"_ _2\"></span>oth in<span class=\"_ _2\"></span>com<span class=\"_ _2\"></span>e and c<span class=\"_ _2\"></span>ap<span class=\"_ _2\"></span>ita<span class=\"_ _2\"></span>l gai<span class=\"_ _2\"></span>ns, a<span class=\"_ _2\"></span>re exem<span class=\"_ _2\"></span>pt from U<span class=\"_ _2\"></span>K ta<span class=\"_ _2\"></span>xatio<span class=\"_ _2\"></span>n. T<span class=\"_ _2\"></span>he Co<span class=\"_ _2\"></span>mp<span class=\"_ _2\"></span>any inte<span class=\"_ _2\"></span>nds to con<span class=\"_ _2\"></span>duc<span class=\"_ _2\"></span>t it<span class=\"_ _2\"></span>s af<span class=\"_ _2\"></span>fai<span class=\"_ _2\"></span>rs so a<span class=\"_ _2\"></span>s to enab<span class=\"_ _2\"></span>le it to conti<span class=\"_ _2\"></span>nue to com<span class=\"_ _2\"></span>ply w<span class=\"_ _2\"></span>ith t<span class=\"_ _2\"></span>he req<span class=\"_ _2\"></span>uirem<span class=\"_ _2\"></span>ent<span class=\"_ _2\"></span>s<span class=\"_ _2\"></span>.",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-324": {
   "value": "The Target Healthcare REIT group was originally established in March 2013 and, following a scheme of arrangement to introduce a parent ",
   "dimensions": {
    "concept": "ifrs-full:NameOfParentEntity",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-4": {
   "value": "Target Healthcare REIT",
   "dimensions": {
    "concept": "ifrs-full:NameOfReportingEntityOrOtherMeansOfIdentification",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-5": {
   "value": "United Kingdom",
   "dimensions": {
    "concept": "ifrs-full:CountryOfIncorporation",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-6": {
   "value": "56354000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-7": {
   "value": "11308000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-8": {
   "value": "67662000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-9": {
   "value": "48807000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-10": {
   "value": "10215000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-11": {
   "value": "59022000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-12": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:OtherRentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-13": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:OtherRentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-14": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:OtherRentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-15": {
   "value": "796000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:OtherRentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-16": {
   "value": "3877000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:OtherRentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-17": {
   "value": "4673000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:OtherRentalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-18": {
   "value": "86000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-19": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-20": {
   "value": "86000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-21": {
   "value": "164000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-22": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-23": {
   "value": "164000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-24": {
   "value": "56440000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Revenue",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-25": {
   "value": "11308000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Revenue",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-26": {
   "value": "67748000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Revenue",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-27": {
   "value": "49767000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Revenue",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-28": {
   "value": "14092000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Revenue",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-29": {
   "value": "63859000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Revenue",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-30": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesGainsOnRevaluationOfInvestmentProperties",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-31": {
   "value": "-54021000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesGainsOnRevaluationOfInvestmentProperties",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-32": {
   "value": "-54021000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesGainsOnRevaluationOfInvestmentProperties",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-33": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesGainsOnRevaluationOfInvestmentProperties",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-34": {
   "value": "5553000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesGainsOnRevaluationOfInvestmentProperties",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-35": {
   "value": "5553000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesGainsOnRevaluationOfInvestmentProperties",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-36": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:GainsOnInvestmentPropertiesRealised",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-37": {
   "value": "575000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:GainsOnInvestmentPropertiesRealised",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-38": {
   "value": "575000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:GainsOnInvestmentPropertiesRealised",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-39": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:GainsOnInvestmentPropertiesRealised",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-40": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:GainsOnInvestmentPropertiesRealised",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-41": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:GainsOnInvestmentPropertiesRealised",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-42": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesOnRevaluationOfPropertiesHeldForSale",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-43": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesOnRevaluationOfPropertiesHeldForSale",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-44": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesOnRevaluationOfPropertiesHeldForSale",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-45": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesOnRevaluationOfPropertiesHeldForSale",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-46": {
   "value": "7000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesOnRevaluationOfPropertiesHeldForSale",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-47": {
   "value": "7000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:LossesOnRevaluationOfPropertiesHeldForSale",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-48": {
   "value": "56440000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-49": {
   "value": "-42138000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-50": {
   "value": "14302000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-51": {
   "value": "49767000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-52": {
   "value": "19638000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-53": {
   "value": "69405000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-54": {
   "value": "7428000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:InvestmentManagementFee",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-55": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:InvestmentManagementFee",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-56": {
   "value": "7428000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:InvestmentManagementFee",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-57": {
   "value": "7307000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:InvestmentManagementFee",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-58": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:InvestmentManagementFee",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-59": {
   "value": "7307000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:InvestmentManagementFee",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-60": {
   "value": "264000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:CreditLossAllowanceAndBadDebts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-61": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:CreditLossAllowanceAndBadDebts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-62": {
   "value": "264000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:CreditLossAllowanceAndBadDebts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-63": {
   "value": "3232000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:CreditLossAllowanceAndBadDebts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-64": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:CreditLossAllowanceAndBadDebts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-65": {
   "value": "3232000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:CreditLossAllowanceAndBadDebts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-66": {
   "value": "3046000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherExpenseByNature",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-67": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherExpenseByNature",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-68": {
   "value": "3046000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherExpenseByNature",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-69": {
   "value": "3163000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherExpenseByNature",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-70": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherExpenseByNature",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-71": {
   "value": "3163000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:OtherExpenseByNature",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-72": {
   "value": "10738000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalExpenditure",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-73": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalExpenditure",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-74": {
   "value": "10738000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalExpenditure",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-75": {
   "value": "13702000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalExpenditure",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-76": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalExpenditure",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-77": {
   "value": "13702000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalExpenditure",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-78": {
   "value": "45702000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:ProfitLossBeforeFinanceCostsAndTaxation",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-79": {
   "value": "-42138000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:ProfitLossBeforeFinanceCostsAndTaxation",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-80": {
   "value": "3564000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:ProfitLossBeforeFinanceCostsAndTaxation",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-81": {
   "value": "36065000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:ProfitLossBeforeFinanceCostsAndTaxation",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-82": {
   "value": "19638000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:ProfitLossBeforeFinanceCostsAndTaxation",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-83": {
   "value": "55703000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:ProfitLossBeforeFinanceCostsAndTaxation",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-84": {
   "value": "134000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RevenueFromInterest",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-85": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RevenueFromInterest",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-86": {
   "value": "134000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RevenueFromInterest",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-87": {
   "value": "71000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RevenueFromInterest",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-88": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RevenueFromInterest",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-89": {
   "value": "71000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RevenueFromInterest",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-90": {
   "value": "9572000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceCosts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-91": {
   "value": "698000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceCosts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-92": {
   "value": "10270000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceCosts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-93": {
   "value": "6671000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceCosts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-94": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceCosts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-95": {
   "value": "6671000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceCosts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-96": {
   "value": "-9438000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceIncomeCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-97": {
   "value": "-698000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceIncomeCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-98": {
   "value": "-10136000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceIncomeCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-99": {
   "value": "-6600000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceIncomeCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-100": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceIncomeCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-101": {
   "value": "-6600000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:FinanceIncomeCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-102": {
   "value": "36264000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLossBeforeTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-103": {
   "value": "-42836000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLossBeforeTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-104": {
   "value": "-6572000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLossBeforeTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-105": {
   "value": "29465000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLossBeforeTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-106": {
   "value": "19638000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLossBeforeTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-107": {
   "value": "49103000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLossBeforeTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-108": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-109": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-110": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-111": {
   "value": "6000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-112": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-113": {
   "value": "6000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-114": {
   "value": "36264000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLoss",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-115": {
   "value": "-42836000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLoss",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-116": {
   "value": "-6572000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLoss",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-117": {
   "value": "29459000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLoss",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-118": {
   "value": "19638000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLoss",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-119": {
   "value": "49097000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLoss",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-120": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-121": {
   "value": "2742000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-122": {
   "value": "2742000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-123": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-124": {
   "value": "2033000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-125": {
   "value": "2033000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-126": {
   "value": "36264000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-127": {
   "value": "-40094000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-128": {
   "value": "-3830000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-129": {
   "value": "29459000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-130": {
   "value": "21671000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-131": {
   "value": "51130000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-132": {
   "value": "0.0585",
   "decimals": 4,
   "dimensions": {
    "concept": "ifrs-full:BasicEarningsLossPerShare",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP/xbrli:shares"
   }
  },
  "fact-133": {
   "value": "-0.0691",
   "decimals": 4,
   "dimensions": {
    "concept": "ifrs-full:BasicEarningsLossPerShare",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP/xbrli:shares"
   }
  },
  "fact-134": {
   "value": "-0.0106",
   "decimals": 4,
   "dimensions": {
    "concept": "ifrs-full:BasicEarningsLossPerShare",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP/xbrli:shares"
   }
  },
  "fact-135": {
   "value": "0.0492",
   "decimals": 4,
   "dimensions": {
    "concept": "ifrs-full:BasicEarningsLossPerShare",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:RevenueMember",
    "unit": "iso4217:GBP/xbrli:shares"
   }
  },
  "fact-136": {
   "value": "0.0328",
   "decimals": 4,
   "dimensions": {
    "concept": "ifrs-full:BasicEarningsLossPerShare",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "targethealthcare:ConsolidatedStatementOfComprehensiveIncomeAxis": "targethealthcare:CapitalMember",
    "unit": "iso4217:GBP/xbrli:shares"
   }
  },
  "fact-137": {
   "value": "0.082",
   "decimals": 4,
   "dimensions": {
    "concept": "ifrs-full:BasicEarningsLossPerShare",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP/xbrli:shares"
   }
  },
  "fact-138": {
   "value": "800155000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:InvestmentProperty",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-139": {
   "value": "857691000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:InvestmentProperty",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-140": {
   "value": "76373000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NoncurrentReceivables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-141": {
   "value": "63651000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NoncurrentReceivables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-142": {
   "value": "6905000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NoncurrentDerivativeFinancialAssets",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-143": {
   "value": "2284000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NoncurrentDerivativeFinancialAssets",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-144": {
   "value": "883433000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NoncurrentAssets",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-145": {
   "value": "923626000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NoncurrentAssets",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-146": {
   "value": "9459000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:TradeAndOtherCurrentReceivables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-147": {
   "value": "5549000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:TradeAndOtherCurrentReceivables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-148": {
   "value": "15366000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashAndCashEquivalents",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-149": {
   "value": "34483000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashAndCashEquivalents",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-150": {
   "value": "24825000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CurrentAssets",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-151": {
   "value": "40032000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CurrentAssets",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-152": {
   "value": "908258000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Assets",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-153": {
   "value": "963658000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Assets",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-154": {
   "value": "227051000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:LongtermBorrowings",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-155": {
   "value": "231383000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:LongtermBorrowings",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-156": {
   "value": "8093000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NoncurrentPayables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-157": {
   "value": "7145000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NoncurrentPayables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-158": {
   "value": "235144000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NoncurrentLiabilities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-159": {
   "value": "238528000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NoncurrentLiabilities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-160": {
   "value": "18306000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:TradeAndOtherCurrentPayables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-161": {
   "value": "26363000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:TradeAndOtherCurrentPayables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-162": {
   "value": "253450000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Liabilities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-163": {
   "value": "264891000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Liabilities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-164": {
   "value": "654808000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NetAssetsLiabilities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-165": {
   "value": "698767000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:NetAssetsLiabilities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-166": {
   "value": "6202000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IssuedCapital",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-167": {
   "value": "6202000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IssuedCapital",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-168": {
   "value": "256633000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:SharePremium",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-169": {
   "value": "256633000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:SharePremium",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-170": {
   "value": "47751000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:MergerReserve",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-171": {
   "value": "47751000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:MergerReserve",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-172": {
   "value": "187887000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:DistributableReserve",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-173": {
   "value": "226461000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:DistributableReserve",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-174": {
   "value": "5026000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ReserveOfCashFlowHedges",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-175": {
   "value": "2284000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ReserveOfCashFlowHedges",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-176": {
   "value": "40914000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CapitalReserve",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-177": {
   "value": "83750000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CapitalReserve",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-178": {
   "value": "110395000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RetainedEarnings",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-179": {
   "value": "75686000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RetainedEarnings",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-180": {
   "value": "654808000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:EquityAttributableToOwnersOfParent",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-181": {
   "value": "698767000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:EquityAttributableToOwnersOfParent",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-182": {
   "value": "1.056",
   "decimals": 3,
   "dimensions": {
    "concept": "targethealthcare:NetAssetValuePerOrdinaryShare",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP/xbrli:shares"
   }
  },
  "fact-183": {
   "value": "1.127",
   "decimals": 3,
   "dimensions": {
    "concept": "targethealthcare:NetAssetValuePerOrdinaryShare",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP/xbrli:shares"
   }
  },
  "fact-184": {
   "value": "6202000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-185": {
   "value": "256633000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-186": {
   "value": "47751000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MergerReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-187": {
   "value": "226461000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "targethealthcare:DistributableReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-188": {
   "value": "2284000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-189": {
   "value": "83750000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:CapitalReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-190": {
   "value": "75686000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-191": {
   "value": "698767000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-192": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-193": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-194": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MergerReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-195": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "targethealthcare:DistributableReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-196": {
   "value": "2742000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-197": {
   "value": "-42836000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:CapitalReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-198": {
   "value": "36264000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-199": {
   "value": "-3830000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-200": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-201": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-202": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MergerReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-203": {
   "value": "38574000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "targethealthcare:DistributableReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-204": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-205": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:CapitalReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-206": {
   "value": "1555000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-207": {
   "value": "40129000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-208": {
   "value": "6202000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-209": {
   "value": "256633000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-210": {
   "value": "47751000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MergerReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-211": {
   "value": "187887000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "targethealthcare:DistributableReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-212": {
   "value": "5026000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-213": {
   "value": "40914000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:CapitalReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-214": {
   "value": "110395000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-215": {
   "value": "654808000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-216": {
   "value": "5115000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-217": {
   "value": "135228000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-218": {
   "value": "47751000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MergerReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-219": {
   "value": "265164000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "targethealthcare:DistributableReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-220": {
   "value": "251000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-221": {
   "value": "64112000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:CapitalReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-222": {
   "value": "47564000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-223": {
   "value": "565185000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-224": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-225": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-226": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MergerReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-227": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "targethealthcare:DistributableReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-228": {
   "value": "2033000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-229": {
   "value": "19638000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:CapitalReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-230": {
   "value": "29459000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-231": {
   "value": "51130000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ComprehensiveIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-232": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-233": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-234": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MergerReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-235": {
   "value": "38703000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "targethealthcare:DistributableReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-236": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-237": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:CapitalReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-238": {
   "value": "1337000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-239": {
   "value": "40040000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaid",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-240": {
   "value": "1087000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IssueOfEquity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-241": {
   "value": "123913000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IssueOfEquity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-242": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IssueOfEquity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MergerReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-243": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IssueOfEquity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "targethealthcare:DistributableReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-244": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IssueOfEquity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-245": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IssueOfEquity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:CapitalReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-246": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IssueOfEquity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-247": {
   "value": "125000000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IssueOfEquity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-248": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ShareIssueRelatedCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-249": {
   "value": "2508000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ShareIssueRelatedCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-250": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ShareIssueRelatedCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MergerReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-251": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ShareIssueRelatedCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "targethealthcare:DistributableReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-252": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ShareIssueRelatedCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-253": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ShareIssueRelatedCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:CapitalReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-254": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ShareIssueRelatedCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-255": {
   "value": "2508000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ShareIssueRelatedCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-256": {
   "value": "6202000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-257": {
   "value": "256633000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-258": {
   "value": "47751000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:MergerReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-259": {
   "value": "226461000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "targethealthcare:DistributableReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-260": {
   "value": "2284000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:ReserveOfCashFlowHedgesMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-261": {
   "value": "83750000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:CapitalReserveMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-262": {
   "value": "75686000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember",
    "unit": "iso4217:GBP"
   }
  },
  "fact-263": {
   "value": "698767000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:Equity",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-264": {
   "value": "-6572000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLossBeforeTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-265": {
   "value": "49103000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProfitLossBeforeTax",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-266": {
   "value": "134000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:AdjustmentsForInterestIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-267": {
   "value": "71000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:AdjustmentsForInterestIncome",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-268": {
   "value": "-10270000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:AdjustmentsForFinanceIncomeCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-269": {
   "value": "-6671000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:AdjustmentsForFinanceIncomeCost",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-270": {
   "value": "-42138000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:AdjustmentsForRevaluationGainsOnInvestmentPropertiesAndMovementsInLeaseIncentivesNetOfAcquisitionCostsWrittenOff",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-271": {
   "value": "19645000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:AdjustmentsForRevaluationGainsOnInvestmentPropertiesAndMovementsInLeaseIncentivesNetOfAcquisitionCostsWrittenOff",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-272": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:AdjustmentsForRevaluationLossesOnPropertiesHeldForSale",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-273": {
   "value": "7000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:AdjustmentsForRevaluationLossesOnPropertiesHeldForSale",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-274": {
   "value": "-4550000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-275": {
   "value": "-3768000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-276": {
   "value": "-325000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-277": {
   "value": "3340000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-278": {
   "value": "40827000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalAdjustmentsRelatingToOperatingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-279": {
   "value": "35637000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalAdjustmentsRelatingToOperatingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-280": {
   "value": "8719000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:InterestPaidClassifiedAsOperatingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-281": {
   "value": "5310000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:InterestPaidClassifiedAsOperatingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-282": {
   "value": "2577000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:PremiumPaidOnInterestRateCapClassifiedAsInvestingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-283": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:PremiumPaidOnInterestRateCapClassifiedAsInvestingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-284": {
   "value": "134000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:InterestReceivedClassifiedAsOperatingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-285": {
   "value": "71000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:InterestReceivedClassifiedAsOperatingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-286": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-287": {
   "value": "6000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-288": {
   "value": "-11162000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashFlowsFromUsedInOperations",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-289": {
   "value": "-5245000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashFlowsFromUsedInOperations",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-290": {
   "value": "29665000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-291": {
   "value": "30392000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-292": {
   "value": "29342000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:PurchaseOfInvestmentProperty",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-293": {
   "value": "206993000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:PurchaseOfInvestmentProperty",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-294": {
   "value": "25789000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProceedsFromSalesOfInvestmentProperty",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-295": {
   "value": "4360000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProceedsFromSalesOfInvestmentProperty",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-296": {
   "value": "-3553000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-297": {
   "value": "-202633000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-298": {
   "value": "0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProceedsFromIssuingShares",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-299": {
   "value": "125000000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProceedsFromIssuingShares",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-300": {
   "value": "-0",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:PaymentsForShareIssueCosts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-301": {
   "value": "2508000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:PaymentsForShareIssueCosts",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-302": {
   "value": "62000000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-303": {
   "value": "222000000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-304": {
   "value": "66750000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-305": {
   "value": "117250000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-306": {
   "value": "205000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:ExpensesOfArrangementOfBankLoanFacilitiesClassifiedAsFinancingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-307": {
   "value": "1839000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:ExpensesOfArrangementOfBankLoanFacilitiesClassifiedAsFinancingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-308": {
   "value": "40274000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaidClassifiedAsFinancingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-309": {
   "value": "39785000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:DividendsPaidClassifiedAsFinancingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-310": {
   "value": "-45229000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-311": {
   "value": "185618000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-312": {
   "value": "-19117000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-313": {
   "value": "13377000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-314": {
   "value": "34483000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashAndCashEquivalents",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-315": {
   "value": "21106000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashAndCashEquivalents",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-316": {
   "value": "15366000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashAndCashEquivalents",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-317": {
   "value": "34483000",
   "decimals": -3,
   "dimensions": {
    "concept": "ifrs-full:CashAndCashEquivalents",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-318": {
   "value": "13516000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:MovementInFixedOrGuaranteedRentReviewsAndLeaseIncentives",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-319": {
   "value": "12148000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:MovementInFixedOrGuaranteedRentReviewsAndLeaseIncentives",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-320": {
   "value": "-732000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:FixedOrGuaranteedRentReviewsDerecognisedOnDisposalOrReTenanting",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-321": {
   "value": "-3362000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:FixedOrGuaranteedRentReviewsDerecognisedOnDisposalOrReTenanting",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-322": {
   "value": "12784000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalTransactionsWhichDoNotRequireTheUseOfCash",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-323": {
   "value": "8786000",
   "decimals": -3,
   "dimensions": {
    "concept": "targethealthcare:TotalTransactionsWhichDoNotRequireTheUseOfCash",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2021-07-01T00:00:00/2022-07-01T00:00:00",
    "unit": "iso4217:GBP"
   }
  },
  "fact-325": {
   "value": "1. Accounting policies (a) Basis of preparation A summary of the principal accounting policies, all of which have been applied consistently throughout the year, is set out below. Basis of accounting These Consolidated Financial Statements have been prepared and approved in accordance with UK-adopted International Financial Reporting Standards (\u2018IFRS\u2019), applicable legal and regulatory requirements of the Companies Act 2006 and the Listing Rules of the Financial Conduct Authority. Where presentational guidance set out in the Statement of Recommended Practice (\u2018SORP\u2019) for investment trust companies issued by the Association of Investment Companies (\u2018AIC\u2019) in July 2022 is consistent with the requirements of IFRS, the Directors have sought to prepare  the Consolidated Financial Statements on a basis compliant with the recommendations of the SORP. The notes and financial statements are presented in pounds sterling (being the functional currency and presentational currency for the Company) and are rounded to the nearest thousand except where otherwise indicated. Applicable standards and interpretations The accounting policies adopted are consistent with those of the previous financial year, except that the following new amendment to the standards has become effective in the current year: \u2013 Annual Improvements to IFRS Standards 2018-2020: The improvements include an amendment to IFRS 9: Financial Instruments \u2013  Fees in the \u201810 per cent\u2019 Test for Derecognition of Financial Liabilities which clarifies the fees a company includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. These amendments do not have an impact on the Consolidated Financial Statements of the Group. Standards issued but not yet effective On 12 February 2021, the IASB issued amendments to IAS 1: Presentation of Financial Statements. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their \u2018significant\u2019 accounting policies with a requirement to disclose their \u2018material\u2019 accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. The amendment is effective for annual periods beginning on or after 1 January 2023. On 12 February 2021, the IASB published \u2018Definition of Accounting Estimates (Amendments to IAS 8)\u2019 to help entities to distinguish between accounting policies, which must be applied retrospectively, and accounting estimates, which are accounted for prospectively. The amendments are effective for annual periods beginning on or after 1 January 2023 and changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. The Group does not consider that the future adoption of any new standards, amended standards or interpretations, in the form currently available, will have any material impact on the Consolidated Financial Statements as presented. Significant estimates and judgements The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for revenue and expenses during the period. The nature of the estimation means that actual outcomes could differ from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected. Revaluation of investment properties (estimate) Significant estimates and assumptions are made in the valuation of the investment properties. The Group engaged an independent valuation specialist to assess fair values for the investment properties. The key assumptions used to determine the fair value of the properties and sensitivity analyses are provided in Notes 9 and 16. Other estimates and judgements Provision for expected credit losses of accrued rent and trade receivables (estimate) The Group uses a provision matrix to calculate expected credit losses for accrued rent and trade receivables. The provision rates are initially based on the Group\u2019s historical observed default rates, adjusted for forward-looking information. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed. Where historical portfolio losses are not thought an appropriate measure of expected credit losses based on the circumstances of particular tenants, the expected credit losses are calculated by identifying scenarios that specify the amount and timing of cash flows for particular outcomes based on the Group\u2019s detailed knowledge, analysis and understanding of the financial standing of each individual rental income debtor (including, where appropriate, consideration of rental guarantees, rental deposits and other forms of surety). The expected credit loss is calculated by weighting the predicted loss under each scenario by an estimate of the probability of each of these outcomes. The assessment of the correlation between historical observed default rates, forward looking information and estimated credit losses  is an estimate, as is the assessment of the correlation between the identification of the potential scenarios that may arise and the estimated probability of each such scenario occurring. The amount of estimated credit losses is sensitive to changes in the financial circumstances of individual tenants and in forward-looking information. Further details are provided in Notes 3 and 16. Going concern Given the potentially significant impact relating to economic conditions in which the Group is operating, including market uncertainty and rising costs, the Directors have continued to place a particular focus on the appropriateness of adopting the going concern basis in preparing  the financial statements for the year ended 30 June 2023. The Group\u2019s going concern assessment particularly considered that: \u2013 The value of the Group\u2019s portfolio of assets significantly exceeds the value of its liabilities; \u2013 The Group is contractually entitled to receive rental income which significantly exceeds its forecast expenses and loan interest;  \u2013 The Group remains within its loan covenants, with the term of its finance facilities having been extended during the period and the quantum of its interest rate hedging increased, resulting in a weighted average term to maturity of 6.2 years at 30 June 2023, an earliest repayment date of November 2025 and a fixed interest rate on \u00a3230 million of the Group\u2019s borrowings; and \u2013 That the continuation vote that was required to be proposed under the Company\u2019s Articles at the AGM held during the year was passed with 100 per cent of the votes cast being in favour of the Company\u2019s continuation. The next continuation vote under the Company\u2019s Articles is required to be proposed at the AGM expected to be held in 2027. The forecast cash flows considered as part of the going concern assessment are based on the twelve months from the date of approval of  the financial statements as contained in the Group\u2019s five-year viability model (as set out on pages 34 and 35). The viability model is based on a severe but plausible downside scenario. Throughout this severe but plausible downside scenario the Group has sufficient cash reserves and is forecast to be able to remain within the financial covenants for each of its loan facilities for a period of at least twelve months from the date of approval of these financial statements. The Group has a significant balance of cash and undrawn debt available and the Group\u2019s current policy is to prudently retain a proportion of this to ensure it can continue to pay the Group\u2019s expenses and loan interest in the unlikely scenario that the level of rental income received deteriorates significantly. The proportion retained will be kept under review dependent on portfolio performance and market conditions. Based on these considerations, the Directors consider that the Group has adequate resources to continue in operational existence to 31 December 2024, which is at least twelve months from the date of issuance of this report. For this reason, they continue to adopt the going concern basis in preparing the financial statements for the year ended 30 June 2023. In preparing the Consolidated Financial Statements, the Directors have considered the impact of climate change risk as set out on page 24. In line with IFRS, investment properties are valued at fair value based on open market valuations as described in Notes 1(h) and 9. The assessment of the open market valuation includes consideration of environmental matters and the condition of each property. The investment properties continue to be monitored by the Investment Manager and key considerations include EPC ratings as summarised at a portfolio level on page 2 and their impact on the properties\u2019 forecast compliance with forthcoming minimum energy efficiency standards. Having assessed the impact of climate change on the Group, the Directors concluded that it is not expected to have a significant impact on the Group\u2019s going concern or viability assessment as described on pages 34 and 35. (b) Basis of consolidation The Consolidated Financial Statements comprise the financial statements of the Company and all of its subsidiaries drawn up to 30 June 2023. Subsidiaries are those entities, including special purpose entities, controlled by the Company and further information is provided in Note 11. Control exists when the Company is exposed, or has rights, to variable returns from its investment with the investee and has the ability to affect those returns through its power over the investee. In assessing control, potential voting rights that presently are exercisable are taken into account. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. In preparing the Consolidated Financial Statements, intra group balances, transactions and unrealised gains or losses have been eliminated in full. Uniform accounting policies are adopted for all companies within the Group. (c) Revenue recognition Rental Income Rental income arising on investment properties is accounted for in the Statement of Comprehensive Income on a straight line basis over the lease term taking account of the following: \u2013 The lease agreements on the properties held within the Group\u2019s property portfolio generally allow for regular increases in the contracted rental level in line with inflation, within a cap and a collar, or at a fixed level. Any rental income from such future fixed and minimum guaranteed rent review uplifts is recalculated to reflect the actual rent uplift realised in the period and is recognised on a straight line basis over the remainder of the lease term; \u2013 Lease incentives are spread evenly over the lease term, even if payments are not made on such a basis. The lease term is the non-cancellable period of the lease together with any further term for which the tenant has the option to continue the lease where, at the inception of the lease, the Directors are reasonably certain that the tenant will exercise that option; and \u2013 Contingent rents are recognised in the period in which they are received. Where income is recognised in advance of the related cash flows due to fixed or minimum guaranteed rent review uplifts or lease incentives, an adjustment is made to ensure that the carrying value of the relevant property including the accrued rent relating to such uplifts or lease incentives does not exceed the external valuation. Any rental income arising in the period due to the recognition of fixed or minimum guaranteed rent review uplifts on a straight line basis is recognised in the capital column of the Statement of Comprehensive Income. Other Rental Income Surrender premiums receivable are recognised on the completion of a deed of surrender and are recognised in revenue where the receipt is  in compensation for a reduction in rent or the granting of a rent free period to an incoming tenant, and in capital when the premium received is in compensation for a reduction in the capital value of the relevant property as a result of the tenant\u2019s surrender of the lease. Interest Income Interest income is accounted for on an accruals basis. Service charges and expenses recoverable from tenants Income arising from expenses recharged to tenants is recognised in the period in which the compensation becomes receivable. Service charges and other such receipts are included gross of the related costs, as the Directors consider the Group acts as principal in this respect. Property-related expenses which are not recoverable from tenants are recognised in expenses on an accruals basis. (d) Expenses Expenses are accounted for on an accruals basis and are inclusive of irrecoverable VAT. The Group\u2019s investment management and administration fees, finance costs and all other expenses are charged through the Statement of Comprehensive Income and are charged to revenue, except where such costs relate wholly to capital matters such as the reorganisation of the Group\u2019s equity structure or the early repayment of its external loan facilities. (e) Dividends Dividends are accounted for in the period in which they are paid. (f) Taxation Taxation on the profit or loss for the period not exempt under UK-REIT regulations comprises current and deferred tax. Taxation is recognised in the Statement of Comprehensive Income except to the extent that it relates to items recognised as direct movements in equity, in which case it is also recognised as a direct movement in equity. Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantively enacted at the balance sheet date. Deferred income tax is provided using the liability method on all temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred income tax assets are recognised only to the extent that it is probable that taxable profit will be available against which deductible temporary differences, carried forward tax credits or tax losses can be utilised. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities. In determining the expected manner of realisation of an asset the Directors consider that the Group will recover the value of investment property through sale. Deferred income tax relating to items recognised directly in equity is recognised in equity and not in profit or loss. Entry to UK-REIT Regime The Group entered the UK-REIT regime with effect from 1 June 2013. The Company entered the Group REIT regime with effect from 7 August 2019, the date at which it become the parent company of the Group. The Group\u2019s subsidiaries all enter the Group REIT regime on acquisition/ incorporation. Entry to the regime results in, subject to continuing relevant UK-REIT criteria being met, the profits of the Group\u2019s property rental business, comprising both income and capital gains, being exempt from UK taxation. The Group ensures that it complies with the UK-REIT regulations through monitoring the ongoing conditions required to maintain REIT status. (g) Property acquisitions Where property is acquired, via corporate acquisitions or otherwise, management considers the substance of the assets and activities of the acquired entity in determining whether the acquisition represents the acquisition of a business or the acquisition of an asset. Where such acquisitions are not judged to be an acquisition of a business, they are not treated as business combinations. Rather, the cost to acquire the corporate entity is allocated between the identifiable assets and liabilities of the entity based on their relative fair values at the acquisition date. Accordingly, no goodwill or additional deferred taxation arises. Otherwise, acquisitions are accounted for as business combinations. (h) Investment properties Investment properties consist of land and buildings (principally care homes) which are not occupied for use by, or in the operations of, the Group, nor for sale in the ordinary course of business, but are held to earn rental income together with the potential for capital and income growth. Investment properties are initially recognised at cost, being the fair value of consideration given, including transaction costs associated with the investment property. Any subsequent capital expenditure incurred in improving investment properties is capitalised in the period incurred and included within the book cost of the property. For properties subject to contingent payment clauses within their purchase agreements, which will result in a further payment if certain performance measures are met, this payment is recognised as a liability when the contracted performance conditions have been met and  a reliable estimate can be made of the amount. Any payment made will result in an increase in rental income receivable from the tenant, to maintain the investment yield from the property, and therefore an asset of approximately equal value is recognised to reflect the fair value of this increase in rental income. Development interest (where income is receivable from a developer in respect of a forward-funding agreement) is deducted from the cost  of investment and shown as a receivable until settled. After initial recognition, investment properties are measured at fair value, with gains and losses recognised in the Statement of Comprehensive Income. Fair value is based on the open market valuation, as provided by Colliers International Healthcare Property Consultants Limited, in their capacity as external valuers, at the balance sheet date using recognised valuation techniques, appropriately adjusted for unamortised lease incentives and rental adjustments. The determination of the fair value of investment properties requires the use of estimates such as future cash flows from assets (such as lettings, tenants\u2019 profiles, future revenue streams, capital values of fixtures and fittings, plant and machinery, any environmental matters and the overall repair and condition of the property) and discount rates applicable to those assets. These estimates are based on local market conditions existing at the balance sheet date. On derecognition, gains and losses on disposals of investment properties are recognised in the Statement of Comprehensive Income and transferred to the Capital Reserve. Recognition and derecognition occurs on the completion of a sale between a willing buyer and a willing seller. (i) Properties held for sale Properties held for sale consist of properties whose carrying value is expected to be recovered principally through a sale transaction rather than continuing use and which are available for immediate sale in their present condition. They are initially recognised at cost, being the fair value of consideration given, and subsequently measured at fair value, with gains and losses recognised in the Statement of Comprehensive Income. Fair value is based on the open market valuation, as provided by Colliers International Healthcare Property Consultants Limited, in their capacity as external valuers, at the balance sheet date using recognised valuation techniques. (j) Cash and cash equivalents Cash and cash equivalents consist of cash in hand and short-term deposits in banks with an original maturity of three months or less. (k) Rent and other receivables Rent receivables are carried at amortised cost. A provision for impairment of trade receivables is calculated through the expected credit loss method in accordance with IFRS 9. As part of this expected credit loss process the following is taken into account: significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganisation, and default or delinquency in payments (more than 30 days overdue). The carrying amount of the asset is reduced through use of an allowance account and the amount of loss is recognised in the Statement of Comprehensive Income in other expenses, separately disclosed as an impairment. Bad debts are written off once all avenues to recover the debt have been exhausted and the lease has ended, or a formal settlement agreement has been reached. Other incentives provided to tenants and fixed or guaranteed rental uplifts are recognised as an asset and amortised over the period from  the date of lease commencement to the earliest termination date. (l) Interest-bearing bank loans and borrowings All bank loans and borrowings are initially recognised at cost, being the fair value of the consideration received net of arrangement costs associated with the borrowing. After initial recognition, all interest bearing loans and borrowings are subsequently measured at amortised  cost using the effective interest method. Amortised cost is calculated by taking into account any loan arrangement costs and any discount  or premium on settlement. (m) Derivative financial instruments The Group uses derivative financial instruments to hedge its risk associated with interest rate fluctuations. The Group\u2019s policy is not to trade  in derivative instruments. Derivative instruments are initially recognised in the Statement of Financial Position at their fair value. Fair value is determined by using a  model to calculate the net present value of future market interest rates or by using market values for similar instruments. Transaction costs  are expensed immediately. The effective portion of the gains or losses arising on the fair value of cash flow hedges in the form of derivative instruments is reported through Other Comprehensive Income and are recognised through the Hedging Reserve. The ineffective portion is recognised through  profit or loss in the Statement of Comprehensive Income. On maturity, or early redemption, of the derivative instrument the unrealised gains or losses arising from cash flow hedges in the form of derivative instruments, initially recognised in Other Comprehensive Income, are reclassified to profit or loss when the hedged forecast transaction is ultimately recognised in the profit or loss, or when the forecast transaction is no longer expected to occur. The Group considers that its interest rate derivatives qualify for hedge accounting when the following criteria are satisfied: \u2013 The instruments must be related to an asset or liability; \u2013 They must change the character of the interest rate by converting a variable rate to a fixed rate or vice versa; \u2013 They must match the principal amounts and maturity dates of the hedged items; \u2013 As cash-flow hedges, the forecast transactions (incurring interest payable on the bank loans) that are subject to the hedges must be highly probable and must present an exposure to variations in cash flows that could ultimately affect the profit or loss; \u2013 The hedge must be effective meaning that there must be an economic relationship between the hedged item and the hedging instrument; the effect of credit risk must not dominate the value changes that result from that economic relationship; and the hedge ratio of the hedging relationship must be the same as that resulting from the quantity of the hedged item that the Group actually hedges and the quantity of the hedging instrument that the Group actually uses to hedge that quantity of hedged item; and \u2013 At the inception of the hedge there must be formal designation and documentation of the hedging relationship and the Group\u2019s risk management objective and strategy for undertaking the hedge. (n) Reserves Share Premium The share premium account represents the difference between the issue price of shares and their nominal value (excluding those issued  as part of the Group reconstruction). This reserve is non-distributable. Merger Reserve The merger reserve arose on the reconstruction of the Group in August 2019 (the \u2018Group Reconstruction\u2019) and represents the difference between the nominal value and the fair value of the shares issued by the Company in exchange for the shares of the Group\u2019s previous parent company, Target Healthcare REIT Limited. This reserve is non-distributable. Distributable Reserve The distributable reserve represents the balance arising following the reduction of the nominal value of the shares issued as part of the  Group Reconstruction from \u00a31.00 per share to \u00a30.01 per share, as approved by the High Court in September 2019. The distributable reserve was reduced by the difference between the fair value of the shares allotted by the Company, in exchange for the shares of Target Healthcare REIT Limited, and the stated capital of Target Healthcare REIT Limited immediately prior to the Group Reconstruction. This reserve is distributable. Any dividends paid in excess of the balance of the revenue reserve in the Company Financial Statements will be charged to this reserve. Hedging Reserve The following are accounted for in the hedging reserve: \u2013 Increases and decreases in the fair value of interest rate derivatives held at the period end. Capital Reserve The following are accounted for in the capital reserve: \u2013 Gains and losses on the disposal of investment properties; \u2013 Gains and losses on the disposal of properties held for sale; \u2013 Increases and decreases in the fair value of investment properties and properties held for sale which are held at the period end; \u2013 Rent adjustments which represent the effect of spreading uplifts and incentives; \u2013 Other expenses or finance costs charged to the capital column of the Statement of Comprehensive Income; \u2013 Taxation arising on the acquisition or disposal of investment properties or properties held for sale; \u2013 Recovery of any cost/tax where the original expense/tax has also been charged to capital; and \u2013 The buyback of shares into, and resale of shares from, treasury. Revenue Reserve The net profit/(loss) arising in the revenue column of the Statement of Comprehensive Income is added to or deducted from this reserve which, in addition to the distributable reserve, is available for paying dividends.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-326": {
   "value": "(a) Basis of preparation A summary of the principal accounting policies, all of which have been applied consistently throughout the year, is set out below. Basis of accounting These Consolidated Financial Statements have been prepared and approved in accordance with UK-adopted International Financial Reporting Standards (\u2018IFRS\u2019), applicable legal and regulatory requirements of the Companies Act 2006 and the Listing Rules of the Financial Conduct Authority. Where presentational guidance set out in the Statement of Recommended Practice (\u2018SORP\u2019) for investment trust companies issued by the Association of Investment Companies (\u2018AIC\u2019) in July 2022 is consistent with the requirements of IFRS, the Directors have sought to prepare  the Consolidated Financial Statements on a basis compliant with the recommendations of the SORP. The notes and financial statements are presented in pounds sterling (being the functional currency and presentational currency for the Company) and are rounded to the nearest thousand except where otherwise indicated. Applicable standards and interpretations The accounting policies adopted are consistent with those of the previous financial year, except that the following new amendment to the standards has become effective in the current year: \u2013 Annual Improvements to IFRS Standards 2018-2020: The improvements include an amendment to IFRS 9: Financial Instruments \u2013  Fees in the \u201810 per cent\u2019 Test for Derecognition of Financial Liabilities which clarifies the fees a company includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. These amendments do not have an impact on the Consolidated Financial Statements of the Group. Standards issued but not yet effective On 12 February 2021, the IASB issued amendments to IAS 1: Presentation of Financial Statements. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their \u2018significant\u2019 accounting policies with a requirement to disclose their \u2018material\u2019 accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. The amendment is effective for annual periods beginning on or after 1 January 2023. On 12 February 2021, the IASB published \u2018Definition of Accounting Estimates (Amendments to IAS 8)\u2019 to help entities to distinguish between accounting policies, which must be applied retrospectively, and accounting estimates, which are accounted for prospectively. The amendments are effective for annual periods beginning on or after 1 January 2023 and changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. The Group does not consider that the future adoption of any new standards, amended standards or interpretations, in the form currently available, will have any material impact on the Consolidated Financial Statements as presented. Significant estimates and judgements The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for revenue and expenses during the period. The nature of the estimation means that actual outcomes could differ from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected. Revaluation of investment properties (estimate) Significant estimates and assumptions are made in the valuation of the investment properties. The Group engaged an independent valuation specialist to assess fair values for the investment properties. The key assumptions used to determine the fair value of the properties and sensitivity analyses are provided in Notes 9 and 16. Other estimates and judgements Provision for expected credit losses of accrued rent and trade receivables (estimate) The Group uses a provision matrix to calculate expected credit losses for accrued rent and trade receivables. The provision rates are initially based on the Group\u2019s historical observed default rates, adjusted for forward-looking information. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed. Where historical portfolio losses are not thought an appropriate measure of expected credit losses based on the circumstances of particular tenants, the expected credit losses are calculated by identifying scenarios that specify the amount and timing of cash flows for particular outcomes based on the Group\u2019s detailed knowledge, analysis and understanding of the financial standing of each individual rental income debtor (including, where appropriate, consideration of rental guarantees, rental deposits and other forms of surety). The expected credit loss is calculated by weighting the predicted loss under each scenario by an estimate of the probability of each of these outcomes. The assessment of the correlation between historical observed default rates, forward looking information and estimated credit losses  is an estimate, as is the assessment of the correlation between the identification of the potential scenarios that may arise and the estimated probability of each such scenario occurring. The amount of estimated credit losses is sensitive to changes in the financial circumstances of individual tenants and in forward-looking information. Further details are provided in Notes 3 and 16. Going concern Given the potentially significant impact relating to economic conditions in which the Group is operating, including market uncertainty and rising costs, the Directors have continued to place a particular focus on the appropriateness of adopting the going concern basis in preparing  the financial statements for the year ended 30 June 2023. The Group\u2019s going concern assessment particularly considered that: \u2013 The value of the Group\u2019s portfolio of assets significantly exceeds the value of its liabilities; \u2013 The Group is contractually entitled to receive rental income which significantly exceeds its forecast expenses and loan interest;  \u2013 The Group remains within its loan covenants, with the term of its finance facilities having been extended during the period and the quantum of its interest rate hedging increased, resulting in a weighted average term to maturity of 6.2 years at 30 June 2023, an earliest repayment date of November 2025 and a fixed interest rate on \u00a3230 million of the Group\u2019s borrowings; and \u2013 That the continuation vote that was required to be proposed under the Company\u2019s Articles at the AGM held during the year was passed with 100 per cent of the votes cast being in favour of the Company\u2019s continuation. The next continuation vote under the Company\u2019s Articles is required to be proposed at the AGM expected to be held in 2027. The forecast cash flows considered as part of the going concern assessment are based on the twelve months from the date of approval of  the financial statements as contained in the Group\u2019s five-year viability model (as set out on pages 34 and 35). The viability model is based on a severe but plausible downside scenario. Throughout this severe but plausible downside scenario the Group has sufficient cash reserves and is forecast to be able to remain within the financial covenants for each of its loan facilities for a period of at least twelve months from the date of approval of these financial statements. The Group has a significant balance of cash and undrawn debt available and the Group\u2019s current policy is to prudently retain a proportion of this to ensure it can continue to pay the Group\u2019s expenses and loan interest in the unlikely scenario that the level of rental income received deteriorates significantly. The proportion retained will be kept under review dependent on portfolio performance and market conditions. Based on these considerations, the Directors consider that the Group has adequate resources to continue in operational existence to 31 December 2024, which is at least twelve months from the date of issuance of this report. For this reason, they continue to adopt the going concern basis in preparing the financial statements for the year ended 30 June 2023. In preparing the Consolidated Financial Statements, the Directors have considered the impact of climate change risk as set out on page 24. In line with IFRS, investment properties are valued at fair value based on open market valuations as described in Notes 1(h) and 9. The assessment of the open market valuation includes consideration of environmental matters and the condition of each property. The investment properties continue to be monitored by the Investment Manager and key considerations include EPC ratings as summarised at a portfolio level on page 2 and their impact on the properties\u2019 forecast compliance with forthcoming minimum energy efficiency standards. Having assessed the impact of climate change on the Group, the Directors concluded that it is not expected to have a significant impact on the Group\u2019s going concern or viability assessment as described on pages 34 and 35. ",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-361": {
   "value": "Basis of accounting These Consolidated Financial Statements have been prepared and approved in accordance with UK-adopted International Financial Reporting Standards (\u2018IFRS\u2019), applicable legal and regulatory requirements of the Companies Act 2006 and the Listing Rules of the Financial Conduct Authority. Where presentational guidance set out in the Statement of Recommended Practice (\u2018SORP\u2019) for investment trust companies issued by the Association of Investment Companies (\u2018AIC\u2019) in July 2022 is consistent with the requirements of IFRS, the Directors have sought to prepare  the Consolidated Financial Statements on a basis compliant with the recommendations of the SORP. ",
   "dimensions": {
    "concept": "ifrs-full:StatementOfIFRSCompliance",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-362": {
   "value": "The notes and financial statements are presented in pounds sterling (being the functional currency and presentational currency for the Company) and are rounded to the nearest thousand except where otherwise indicated. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-381": {
   "value": "Applicable standards and interpretations The accounting policies adopted are consistent with those of the previous financial year, except that the following new amendment to the standards has become effective in the current year: \u2013 Annual Improvements to IFRS Standards 2018-2020: The improvements include an amendment to IFRS 9: Financial Instruments \u2013  Fees in the \u201810 per cent\u2019 Test for Derecognition of Financial Liabilities which clarifies the fees a company includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. These amendments do not have an impact on the Consolidated Financial Statements of the Group. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-363": {
   "value": "Applicable standards and interpretations The accounting policies adopted are consistent with those of the previous financial year, except that the following new amendment to the standards has become effective in the current year: \u2013 Annual Improvements to IFRS Standards 2018-2020: The improvements include an amendment to IFRS 9: Financial Instruments \u2013  Fees in the \u201810 per cent\u2019 Test for Derecognition of Financial Liabilities which clarifies the fees a company includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. These amendments do not have an impact on the Consolidated Financial Statements of the Group. Standards issued but not yet effective On 12 February 2021, the IASB issued amendments to IAS 1: Presentation of Financial Statements. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their \u2018significant\u2019 accounting policies with a requirement to disclose their \u2018material\u2019 accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. The amendment is effective for annual periods beginning on or after 1 January 2023. On 12 February 2021, the IASB published \u2018Definition of Accounting Estimates (Amendments to IAS 8)\u2019 to help entities to distinguish between accounting policies, which must be applied retrospectively, and accounting estimates, which are accounted for prospectively. The amendments are effective for annual periods beginning on or after 1 January 2023 and changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. The Group does not consider that the future adoption of any new standards, amended standards or interpretations, in the form currently available, will have any material impact on the Consolidated Financial Statements as presented. ",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-382": {
   "value": "Standards issued but not yet effective On 12 February 2021, the IASB issued amendments to IAS 1: Presentation of Financial Statements. The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their \u2018significant\u2019 accounting policies with a requirement to disclose their \u2018material\u2019 accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. The amendment is effective for annual periods beginning on or after 1 January 2023. On 12 February 2021, the IASB published \u2018Definition of Accounting Estimates (Amendments to IAS 8)\u2019 to help entities to distinguish between accounting policies, which must be applied retrospectively, and accounting estimates, which are accounted for prospectively. The amendments are effective for annual periods beginning on or after 1 January 2023 and changes in accounting policies and changes in accounting estimates that occur on or after the start of that period. The Group does not consider that the future adoption of any new standards, amended standards or interpretations, in the form currently available, will have any material impact on the Consolidated Financial Statements as presented. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-364": {
   "value": "Significant estimates and judgements The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for revenue and expenses during the period. The nature of the estimation means that actual outcomes could differ from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected. Revaluation of investment properties (estimate) Significant estimates and assumptions are made in the valuation of the investment properties. The Group engaged an independent valuation specialist to assess fair values for the investment properties. The key assumptions used to determine the fair value of the properties and sensitivity analyses are provided in Notes 9 and 16. Other estimates and judgements Provision for expected credit losses of accrued rent and trade receivables (estimate) The Group uses a provision matrix to calculate expected credit losses for accrued rent and trade receivables. The provision rates are initially based on the Group\u2019s historical observed default rates, adjusted for forward-looking information. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed. Where historical portfolio losses are not thought an appropriate measure of expected credit losses based on the circumstances of particular tenants, the expected credit losses are calculated by identifying scenarios that specify the amount and timing of cash flows for particular outcomes based on the Group\u2019s detailed knowledge, analysis and understanding of the financial standing of each individual rental income debtor (including, where appropriate, consideration of rental guarantees, rental deposits and other forms of surety). The expected credit loss is calculated by weighting the predicted loss under each scenario by an estimate of the probability of each of these outcomes. The assessment of the correlation between historical observed default rates, forward looking information and estimated credit losses  is an estimate, as is the assessment of the correlation between the identification of the potential scenarios that may arise and the estimated probability of each such scenario occurring. The amount of estimated credit losses is sensitive to changes in the financial circumstances of individual tenants and in forward-looking information. Further details are provided in Notes 3 and 16. ",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-365": {
   "value": "Going concern Given the potentially significant impact relating to economic conditions in which the Group is operating, including market uncertainty and rising costs, the Directors have continued to place a particular focus on the appropriateness of adopting the going concern basis in preparing  the financial statements for the year ended 30 June 2023. The Group\u2019s going concern assessment particularly considered that: \u2013 The value of the Group\u2019s portfolio of assets significantly exceeds the value of its liabilities; \u2013 The Group is contractually entitled to receive rental income which significantly exceeds its forecast expenses and loan interest;  \u2013 The Group remains within its loan covenants, with the term of its finance facilities having been extended during the period and the quantum of its interest rate hedging increased, resulting in a weighted average term to maturity of 6.2 years at 30 June 2023, an earliest repayment date of November 2025 and a fixed interest rate on \u00a3230 million of the Group\u2019s borrowings; and \u2013 That the continuation vote that was required to be proposed under the Company\u2019s Articles at the AGM held during the year was passed with 100 per cent of the votes cast being in favour of the Company\u2019s continuation. The next continuation vote under the Company\u2019s Articles is required to be proposed at the AGM expected to be held in 2027. The forecast cash flows considered as part of the going concern assessment are based on the twelve months from the date of approval of  the financial statements as contained in the Group\u2019s five-year viability model (as set out on pages 34 and 35). The viability model is based on a severe but plausible downside scenario. Throughout this severe but plausible downside scenario the Group has sufficient cash reserves and is forecast to be able to remain within the financial covenants for each of its loan facilities for a period of at least twelve months from the date of approval of these financial statements. The Group has a significant balance of cash and undrawn debt available and the Group\u2019s current policy is to prudently retain a proportion of this to ensure it can continue to pay the Group\u2019s expenses and loan interest in the unlikely scenario that the level of rental income received deteriorates significantly. The proportion retained will be kept under review dependent on portfolio performance and market conditions. Based on these considerations, the Directors consider that the Group has adequate resources to continue in operational existence to 31 December 2024, which is at least twelve months from the date of issuance of this report. For this reason, they continue to adopt the going concern basis in preparing the financial statements for the year ended 30 June 2023. In preparing the Consolidated Financial Statements, the Directors have considered the impact of climate change risk as set out on page 24. In line with IFRS, investment properties are valued at fair value based on open market valuations as described in Notes 1(h) and 9. The assessment of the open market valuation includes consideration of environmental matters and the condition of each property. The investment properties continue to be monitored by the Investment Manager and key considerations include EPC ratings as summarised at a portfolio level on page 2 and their impact on the properties\u2019 forecast compliance with forthcoming minimum energy efficiency standards. Having assessed the impact of climate change on the Group, the Directors concluded that it is not expected to have a significant impact on the Group\u2019s going concern or viability assessment as described on pages 34 and 35. ",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfGoingConcernExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-327": {
   "value": "(b) Basis of consolidation The Consolidated Financial Statements comprise the financial statements of the Company and all of its subsidiaries drawn up to 30 June 2023. Subsidiaries are those entities, including special purpose entities, controlled by the Company and further information is provided in Note 11. Control exists when the Company is exposed, or has rights, to variable returns from its investment with the investee and has the ability to affect those returns through its power over the investee. In assessing control, potential voting rights that presently are exercisable are taken into account. The financial statements of subsidiaries are included in the Consolidated Financial Statements from the date that control commences until the date that control ceases. In preparing the Consolidated Financial Statements, intra group balances, transactions and unrealised gains or losses have been eliminated in full. Uniform accounting policies are adopted for all companies within the Group. ",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-328": {
   "value": "(c) Revenue recognition Rental Income Rental income arising on investment properties is accounted for in the Statement of Comprehensive Income on a straight line basis over the lease term taking account of the following: \u2013 The lease agreements on the properties held within the Group\u2019s property portfolio generally allow for regular increases in the contracted rental level in line with inflation, within a cap and a collar, or at a fixed level. Any rental income from such future fixed and minimum guaranteed rent review uplifts is recalculated to reflect the actual rent uplift realised in the period and is recognised on a straight line basis over the remainder of the lease term; \u2013 Lease incentives are spread evenly over the lease term, even if payments are not made on such a basis. The lease term is the non-cancellable period of the lease together with any further term for which the tenant has the option to continue the lease where, at the inception of the lease, the Directors are reasonably certain that the tenant will exercise that option; and \u2013 Contingent rents are recognised in the period in which they are received. Where income is recognised in advance of the related cash flows due to fixed or minimum guaranteed rent review uplifts or lease incentives, an adjustment is made to ensure that the carrying value of the relevant property including the accrued rent relating to such uplifts or lease incentives does not exceed the external valuation. Any rental income arising in the period due to the recognition of fixed or minimum guaranteed rent review uplifts on a straight line basis is recognised in the capital column of the Statement of Comprehensive IncomeOther Rental Income Surrender premiums receivable are recognised on the completion of a deed of surrender and are recognised in revenue where the receipt is  in compensation for a reduction in rent or the granting of a rent free period to an incoming tenant, and in capital when the premium received is in compensation for a reduction in the capital value of the relevant property as a result of the tenant\u2019s surrender of the lease. Interest Income Interest income is accounted for on an accruals basis. Service charges and expenses recoverable from tenants Income arising from expenses recharged to tenants is recognised in the period in which the compensation becomes receivable. Service charges and other such receipts are included gross of the related costs, as the Directors consider the Group acts as principal in this respect. Property-related expenses which are not recoverable from tenants are recognised in expenses on an accruals basis. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-329": {
   "value": "(d) Expenses Expenses are accounted for on an accruals basis and are inclusive of irrecoverable VAT. The Group\u2019s investment management and administration fees, finance costs and all other expenses are charged through the Statement of Comprehensive Income and are charged to revenue, except where such costs relate wholly to capital matters such as the reorganisation of the Group\u2019s equity structure or the early repayment of its external loan facilities. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForExpensesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-330": {
   "value": "(e) Dividends Dividends are accounted for in the period in which they are paid. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForDividendsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-331": {
   "value": "(f) Taxation Taxation on the profit or loss for the period not exempt under UK-REIT regulations comprises current and deferred tax. Taxation is recognised in the Statement of Comprehensive Income except to the extent that it relates to items recognised as direct movements in equity, in which case it is also recognised as a direct movement in equity. Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantively enacted at the balance sheet date. Deferred income tax is provided using the liability method on all temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred income tax assets are recognised only to the extent that it is probable that taxable profit will be available against which deductible temporary differences, carried forward tax credits or tax losses can be utilised. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities. In determining the expected manner of realisation of an asset the Directors consider that the Group will recover the value of investment property through sale. Deferred income tax relating to items recognised directly in equity is recognised in equity and not in profit or loss. Entry to UK-REIT Regime The Group entered the UK-REIT regime with effect from 1 June 2013. The Company entered the Group REIT regime with effect from 7 August 2019, the date at which it become the parent company of the Group. The Group\u2019s subsidiaries all enter the Group REIT regime on acquisition/ incorporation. Entry to the regime results in, subject to continuing relevant UK-REIT criteria being met, the profits of the Group\u2019s property rental business, comprising both income and capital gains, being exempt from UK taxation. The Group ensures that it complies with the UK-REIT regulations through monitoring the ongoing conditions required to maintain REIT status. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-366": {
   "value": "(f) Taxation Taxation on the profit or loss for the period not exempt under UK-REIT regulations comprises current and deferred tax. Taxation is recognised in the Statement of Comprehensive Income except to the extent that it relates to items recognised as direct movements in equity, in which case it is also recognised as a direct movement in equity. Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantively enacted at the balance sheet date. Deferred income tax is provided using the liability method on all temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred income tax assets are recognised only to the extent that it is probable that taxable profit will be available against which deductible temporary differences, carried forward tax credits or tax losses can be utilised. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities. In determining the expected manner of realisation of an asset the Directors consider that the Group will recover the value of investment property through sale. Deferred income tax relating to items recognised directly in equity is recognised in equity and not in profit or loss. Entry to UK-REIT Regime The Group entered the UK-REIT regime with effect from 1 June 2013. The Company entered the Group REIT regime with effect from 7 August 2019, the date at which it become the parent company of the Group. The Group\u2019s subsidiaries all enter the Group REIT regime on acquisition/ incorporation. Entry to the regime results in, subject to continuing relevant UK-REIT criteria being met, the profits of the Group\u2019s property rental business, comprising both income and capital gains, being exempt from UK taxation. The Group ensures that it complies with the UK-REIT regulations through monitoring the ongoing conditions required to maintain REIT status. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-332": {
   "value": "(g) Property acquisitions Where property is acquired, via corporate acquisitions or otherwise, management considers the substance of the assets and activities of the acquired entity in determining whether the acquisition represents the acquisition of a business or the acquisition of an asset. Where such acquisitions are not judged to be an acquisition of a business, they are not treated as business combinations. Rather, the cost to acquire the corporate entity is allocated between the identifiable assets and liabilities of the entity based on their relative fair values at the acquisition date. Accordingly, no goodwill or additional deferred taxation arises. Otherwise, acquisitions are accounted for as business combinations. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-367": {
   "value": "(g) Property acquisitions Where property is acquired, via corporate acquisitions or otherwise, management considers the substance of the assets and activities of the acquired entity in determining whether the acquisition represents the acquisition of a business or the acquisition of an asset. Where such acquisitions are not judged to be an acquisition of a business, they are not treated as business combinations. Rather, the cost to acquire the corporate entity is allocated between the identifiable assets and liabilities of the entity based on their relative fair values at the acquisition date. Accordingly, no goodwill or additional deferred taxation arises. Otherwise, acquisitions are accounted for as business combinations. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-333": {
   "value": "(h) Investment properties Investment properties consist of land and buildings (principally care homes) which are not occupied for use by, or in the operations of, the Group, nor for sale in the ordinary course of business, but are held to earn rental income together with the potential for capital and income growth. Investment properties are initially recognised at cost, being the fair value of consideration given, including transaction costs associated with the investment property. Any subsequent capital expenditure incurred in improving investment properties is capitalised in the period incurred and included within the book cost of the property. For properties subject to contingent payment clauses within their purchase agreements, which will result in a further payment if certain performance measures are met, this payment is recognised as a liability when the contracted performance conditions have been met and  a reliable estimate can be made of the amount. Any payment made will result in an increase in rental income receivable from the tenant, to maintain the investment yield from the property, and therefore an asset of approximately equal value is recognised to reflect the fair value of this increase in rental income. Development interest (where income is receivable from a developer in respect of a forward-funding agreement) is deducted from the cost  of investment and shown as a receivable until settled. After initial recognition, investment properties are measured at fair value, with gains and losses recognised in the Statement of Comprehensive Income. Fair value is based on the open market valuation, as provided by Colliers International Healthcare Property Consultants Limited, in their capacity as external valuers, at the balance sheet date using recognised valuation techniques, appropriately adjusted for unamortised lease incentives and rental adjustments. The determination of the fair value of investment properties requires the use of estimates such as future cash flows from assets (such as lettings, tenants\u2019 profiles, future revenue streams, capital values of fixtures and fittings, plant and machinery, any environmental matters and the overall repair and condition of the property) and discount rates applicable to those assets. These estimates are based on local market conditions existing at the balance sheet date. On derecognition, gains and losses on disposals of investment properties are recognised in the Statement of Comprehensive Income and transferred to the Capital Reserve. Recognition and derecognition occurs on the completion of a sale between a willing buyer and a willing seller. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForInvestmentPropertyExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-334": {
   "value": "(i) Properties held for sale Properties held for sale consist of properties whose carrying value is expected to be recovered principally through a sale transaction rather than continuing use and which are available for immediate sale in their present condition. They are initially recognised at cost, being the fair value of consideration given, and subsequently measured at fair value, with gains and losses recognised in the Statement of Comprehensive Income. Fair value is based on the open market valuation, as provided by Colliers International Healthcare Property Consultants Limited, in their capacity as external valuers, at the balance sheet date using recognised valuation techniques. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-335": {
   "value": "(j) Cash and cash equivalents Cash and cash equivalents consist of cash in hand and short-term deposits in banks with an original maturity of three months or less. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-336": {
   "value": "(k) Rent and other receivables Rent receivables are carried at amortised cost. A provision for impairment of trade receivables is calculated through the expected credit loss method in accordance with IFRS 9. As part of this expected credit loss process the following is taken into account: significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganisation, and default or delinquency in payments (more than 30 days overdue). The carrying amount of the asset is reduced through use of an allowance account and the amount of loss is recognised in the Statement of Comprehensive Income in other expenses, separately disclosed as an impairment. Bad debts are written off once all avenues to recover the debt have been exhausted and the lease has ended, or a formal settlement agreement has been reached. Other incentives provided to tenants and fixed or guaranteed rental uplifts are recognised as an asset and amortised over the period from  the date of lease commencement to the earliest termination date",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-337": {
   "value": "(l) Interest-bearing bank loans and borrowings All bank loans and borrowings are initially recognised at cost, being the fair value of the consideration received net of arrangement costs associated with the borrowing. After initial recognition, all interest bearing loans and borrowings are subsequently measured at amortised  cost using the effective interest method. Amortised cost is calculated by taking into account any loan arrangement costs and any discount  or premium on settlement. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-383": {
   "value": "(m) Derivative financial instruments The Group uses derivative financial instruments to hedge its risk associated with interest rate fluctuations. The Group\u2019s policy is not to trade  in derivative instruments. Derivative instruments are initially recognised in the Statement of Financial Position at their fair value. Fair value is determined by using a  model to calculate the net present value of future market interest rates or by using market values for similar instruments. Transaction costs  are expensed immediately. The effective portion of the gains or losses arising on the fair value of cash flow hedges in the form of derivative instruments is reported through Other Comprehensive Income and are recognised through the Hedging Reserve. The ineffective portion is recognised through  profit or loss in the Statement of Comprehensive Income. On maturity, or early redemption, of the derivative instrument the unrealised gains or losses arising from cash flow hedges in the form of derivative instruments, initially recognised in Other Comprehensive Income, are reclassified to profit or loss when the hedged forecast transaction is ultimately recognised in the profit or loss, or when the forecast transaction is no longer expected to occur. The Group considers that its interest rate derivatives qualify for hedge accounting when the following criteria are satisfied: \u2013 The instruments must be related to an asset or liability; \u2013 They must change the character of the interest rate by converting a variable rate to a fixed rate or vice versa; \u2013 They must match the principal amounts and maturity dates of the hedged items; \u2013 As cash-flow hedges, the forecast transactions (incurring interest payable on the bank loans) that are subject to the hedges must be highly probable and must present an exposure to variations in cash flows that could ultimately affect the profit or loss; \u2013 The hedge must be effective meaning that there must be an economic relationship between the hedged item and the hedging instrument; the effect of credit risk must not dominate the value changes that result from that economic relationship; and the hedge ratio of the hedging relationship must be the same as that resulting from the quantity of the hedged item that the Group actually hedges and the quantity of the hedging instrument that the Group actually uses to hedge that quantity of hedged item; and \u2013 At the inception of the hedge there must be formal designation and documentation of the hedging relationship and the Group\u2019s risk management objective and strategy for undertaking the hedge. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForHedgingExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-368": {
   "value": "(m) Derivative financial instruments The Group uses derivative financial instruments to hedge its risk associated with interest rate fluctuations. The Group\u2019s policy is not to trade  in derivative instruments. Derivative instruments are initially recognised in the Statement of Financial Position at their fair value. Fair value is determined by using a  model to calculate the net present value of future market interest rates or by using market values for similar instruments. Transaction costs  are expensed immediately. The effective portion of the gains or losses arising on the fair value of cash flow hedges in the form of derivative instruments is reported through Other Comprehensive Income and are recognised through the Hedging Reserve. The ineffective portion is recognised through  profit or loss in the Statement of Comprehensive Income. On maturity, or early redemption, of the derivative instrument the unrealised gains or losses arising from cash flow hedges in the form of derivative instruments, initially recognised in Other Comprehensive Income, are reclassified to profit or loss when the hedged forecast transaction is ultimately recognised in the profit or loss, or when the forecast transaction is no longer expected to occur. The Group considers that its interest rate derivatives qualify for hedge accounting when the following criteria are satisfied: \u2013 The instruments must be related to an asset or liability; \u2013 They must change the character of the interest rate by converting a variable rate to a fixed rate or vice versa; \u2013 They must match the principal amounts and maturity dates of the hedged items; \u2013 As cash-flow hedges, the forecast transactions (incurring interest payable on the bank loans) that are subject to the hedges must be highly probable and must present an exposure to variations in cash flows that could ultimately affect the profit or loss; \u2013 The hedge must be effective meaning that there must be an economic relationship between the hedged item and the hedging instrument; the effect of credit risk must not dominate the value changes that result from that economic relationship; and the hedge ratio of the hedging relationship must be the same as that resulting from the quantity of the hedged item that the Group actually hedges and the quantity of the hedging instrument that the Group actually uses to hedge that quantity of hedged item; and \u2013 At the inception of the hedge there must be formal designation and documentation of the hedging relationship and the Group\u2019s risk management objective and strategy for undertaking the hedge. ",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-338": {
   "value": "(m) Derivative financial instruments The Group uses derivative financial instruments to hedge its risk associated with interest rate fluctuations. The Group\u2019s policy is not to trade  in derivative instruments. Derivative instruments are initially recognised in the Statement of Financial Position at their fair value. Fair value is determined by using a  model to calculate the net present value of future market interest rates or by using market values for similar instruments. Transaction costs  are expensed immediately. The effective portion of the gains or losses arising on the fair value of cash flow hedges in the form of derivative instruments is reported through Other Comprehensive Income and are recognised through the Hedging Reserve. The ineffective portion is recognised through  profit or loss in the Statement of Comprehensive Income. On maturity, or early redemption, of the derivative instrument the unrealised gains or losses arising from cash flow hedges in the form of derivative instruments, initially recognised in Other Comprehensive Income, are reclassified to profit or loss when the hedged forecast transaction is ultimately recognised in the profit or loss, or when the forecast transaction is no longer expected to occur. The Group considers that its interest rate derivatives qualify for hedge accounting when the following criteria are satisfied: \u2013 The instruments must be related to an asset or liability; \u2013 They must change the character of the interest rate by converting a variable rate to a fixed rate or vice versa; \u2013 They must match the principal amounts and maturity dates of the hedged items; \u2013 As cash-flow hedges, the forecast transactions (incurring interest payable on the bank loans) that are subject to the hedges must be highly probable and must present an exposure to variations in cash flows that could ultimately affect the profit or loss; \u2013 The hedge must be effective meaning that there must be an economic relationship between the hedged item and the hedging instrument; the effect of credit risk must not dominate the value changes that result from that economic relationship; and the hedge ratio of the hedging relationship must be the same as that resulting from the quantity of the hedged item that the Group actually hedges and the quantity of the hedging instrument that the Group actually uses to hedge that quantity of hedged item; and \u2013 At the inception of the hedge there must be formal designation and documentation of the hedging relationship and the Group\u2019s risk management objective and strategy for undertaking the hedge",
   "dimensions": {
    "concept": "ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-339": {
   "value": "(n) Reserves Share Premium The share premium account represents the difference between the issue price of shares and their nominal value (excluding those issued  as part of the Group reconstruction). This reserve is non-distributable. Merger Reserve The merger reserve arose on the reconstruction of the Group in August 2019 (the \u2018Group Reconstruction\u2019) and represents the difference between the nominal value and the fair value of the shares issued by the Company in exchange for the shares of the Group\u2019s previous parent company, Target Healthcare REIT Limited. This reserve is non-distributable. Distributable Reserve The distributable reserve represents the balance arising following the reduction of the nominal value of the shares issued as part of the  Group Reconstruction from \u00a31.00 per share to \u00a30.01 per share, as approved by the High Court in September 2019. The distributable reserve was reduced by the difference between the fair value of the shares allotted by the Company, in exchange for the shares of Target Healthcare REIT Limited, and the stated capital of Target Healthcare REIT Limited immediately prior to the Group Reconstruction. This reserve is distributable. Any dividends paid in excess of the balance of the revenue reserve in the Company Financial Statements will be charged to this reserve. Hedging Reserve The following are accounted for in the hedging reserve: \u2013 Increases and decreases in the fair value of interest rate derivatives held at the period end. Capital Reserve The following are accounted for in the capital reserve: \u2013 Gains and losses on the disposal of investment properties; \u2013 Gains and losses on the disposal of properties held for sale; \u2013 Increases and decreases in the fair value of investment properties and properties held for sale which are held at the period end; \u2013 Rent adjustments which represent the effect of spreading uplifts and incentives; \u2013 Other expenses or finance costs charged to the capital column of the Statement of Comprehensive Income; \u2013 Taxation arising on the acquisition or disposal of investment properties or properties held for sale; \u2013 Recovery of any cost/tax where the original expense/tax has also been charged to capital; and \u2013 The buyback of shares into, and resale of shares from, treasury. Revenue Reserve The net profit/(loss) arising in the revenue column of the Statement of Comprehensive Income is added to or deducted from this reserve which, in addition to the distributable reserve, is available for paying dividends.",
   "dimensions": {
    "concept": "targethealthcare:DescriptionOfAccountingPolicyForReserves",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-340": {
   "value": "2. Fee paid to the Investment Manager Year ended 30 June 2023 \u00a3\u2019000 Year ended 30 June 2022 \u00a3\u2019000 Investment management fee 7,428 7,307 Total 7,428 7,307 The Group\u2019s Investment Manager and Alternative Investment Fund Manager (\u2018AIFM\u2019) is Target Fund Managers Limited. The Investment Manager is entitled to an annual management fee calculated on a tiered basis based on the net assets of the Group as set out below. Where applicable, VAT is payable in addition. Net assets of the Group Management fee percentage Up to and including \u00a3500 million 1.05 Above \u00a3500 million and up to and including \u00a3750 million 0.95 Above \u00a3750 million and up to and including \u00a31 billion 0.85 Above \u00a31 billion and up to and including \u00a31.5 billion 0.75 Above \u00a31.5 billion 0.65 The Investment Manager is entitled to an additional fee of \u00a3141,000 per annum (plus VAT), increasing annually in line with inflation, in relation to their appointment as Company Secretary and Administrator to the Group. The Investment Management Agreement can be terminated by either party on 24 months\u2019 written notice. Should the Company terminate the Investment Management Agreement earlier then compensation in lieu of notice will be payable to the Investment Manager. The Investment Management Agreement may be terminated immediately without compensation if the Investment Manager: is in material breach of the agreement; is guilty of negligence, wilful default or fraud; is the subject of insolvency proceedings; or there occurs a change of Key Managers to which the Board has not given its prior consent.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfFeeAndCommissionIncomeExpenseExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-341": {
   "value": "3. Other expenses Year ended 30 June 2023 \u00a3\u2019000 Year ended 30 June 2022 \u00a3\u2019000 Total movement in credit loss allowance  (4,991) 2,865 Bad debts written off 5,255 367 Credit loss allowance charge 264 3,232 Valuation and other professional fees 1,131 1,143 Auditor\u2019s remuneration for: \u2013 statutory audit of the Company 131 118 \u2013 statutory audit of the Company\u2019s subsidiaries 221 230 \u2013 review of interim financial information 16 16 Other taxation compliance and advisory* 258 361 Public relations and marketing 229 327 Directors\u2019 fees 218 214 Secretarial and administration fees 208 177 Direct property costs 182 160 Printing, postage and website 95 111 Listing and Registrar fees 114 102 Other 243 204 Total other expenses 3,046 3,163 *  The other taxation compliance and advisory fees were all paid to parties other than the Company\u2019s Auditor. The valuers of the investment properties, Colliers International Healthcare Property Consultants Limited, have agreed to provide valuation services in respect of the property portfolio. The valuation agreement states that annual fees will be payable quarterly based on rates of  0.05 per cent of the aggregate value of the property portfolio up to \u00a330 million, 0.04 per cent up to \u00a360 million and 0.035 per cent greater than \u00a360 million. Expenses are inclusive of irrecoverable VAT as the Company, and the majority of its subsidiaries, are not VAT registered.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfExpensesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-342": {
   "value": "4. Interest income Year ended 30 June 2023 \u00a3\u2019000 Year ended 30 June 2022 \u00a3\u2019000 Deposit interest 134 71 Total 134 71 5. Finance costs Year ended 30 June 2023 \u00a3\u2019000 Year ended 30 June 2022 \u00a3\u2019000 Interest paid on bank loans 8,949 6,103 Amortisation of loan costs 623 568 Finance and transaction costs relating to the interest rate cap 698 \u2013 Total 10,270 6,671",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfInterestIncomeExpenseExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-369": {
   "value": "4. Interest income Year ended 30 June 2023 \u00a3\u2019000 Year ended 30 June 2022 \u00a3\u2019000 Deposit interest 134 71 Total 134 71 ",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfInterestIncomeExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-370": {
   "value": "5. Finance costs Year ended 30 June 2023 \u00a3\u2019000 Year ended 30 June 2022 \u00a3\u2019000 Interest paid on bank loans 8,949 6,103 Amortisation of loan costs 623 568 Finance and transaction costs relating to the interest rate cap 698 \u2013 Total 10,270 6,671",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfInterestExpenseExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-343": {
   "value": "6. Taxation Year ended 30 June 2023 \u00a3\u2019000 Year ended 30 June 2022 \u00a3\u2019000 Current tax \u2013 6 Adjustment to tax charge for prior years \u2013 \u2013 Total tax charge \u2013 6 A reconciliation of the corporation tax charge applicable to the results at the statutory corporation tax rate to the charge for the year is as follows: Year ended 30 June 2023 \u00a3\u2019000 Year ended 30 June 2022 \u00a3\u2019000 (Loss)/profit before tax (6,572) 49,103 Tax at 20.5% (2022: 19.0%) (1,347) 9,330 Effects of: REIT exempt profits (8,665) (6,671) REIT exempt losses/(gains) 11,152 (1,642) Capital allowances (1,577) (1,642) Excess management expenses carried forward 286 624 Expenses not deductible for tax purposes 151 7 Total tax charge \u2013 6 The Directors intend to conduct the Company\u2019s affairs such that management and control is exercised in the United Kingdom and so that the Company carries on any trade in the United Kingdom. Subject to continuing relevant UK-REIT criteria being met, the profits from the Group\u2019s property rental business, arising from both income and capital gains, are exempt from corporation tax. The Group has unutilised tax losses carried forward in its residual business of \u00a312.5 million at 30 June 2023 (2022: \u00a310.6 million). No deferred tax asset has been recognised on this amount as the Group cannot be certain that there will be taxable profits arising within its residual business from which the future reversal of the deferred tax asset could be deducted.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-344": {
   "value": "7. Dividends Amounts paid as distributions to equity holders during the year to 30 June 2023. Dividend rate (pence per share) Year ended 30 June 2023 \u00a3\u2019000 Fourth interim dividend for the year ended 30 June 2022 1.69 10,482 First interim dividend for the year ended 30 June 2023 1.69 10,482 Second interim dividend for the year ended 30 June 2023 1.69 10,482 Third interim dividend for the year ended 30 June 2023 1.40 8,683 Total 6.47 40,129 Amounts paid as distributions to equity holders during the year to 30 June 2022. Dividend rate (pence per share) Year ended 30 June 2022 \u00a3\u2019000 Fourth interim dividend for the year ended 30 June 2021 1.68 8,594 First interim dividend for the year ended 30 June 2022 1.69 10,482 Second interim dividend for the year ended 30 June 2022 1.69 10,482 Third interim dividend for the year ended 30 June 2022 1.69 10,482 Total 6.75 40,040 It is the policy of the Directors to declare and pay dividends as interim dividends. The Directors do not therefore recommend a final dividend. The fourth interim dividend in respect of the year ended 30 June 2023, of 1.40 pence per share, was paid on 25 August 2023 to shareholders on the register on 11 August 2023 and amounted to \u00a38,683,000. It is the intention of the Directors that the Group will continue to pay dividends quarterly",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfDividendsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-345": {
   "value": "8. Earnings per share and Net Asset Value per share Earnings per share Year ended 30 June 2023 Year ended 30 June 2022 \u00a3\u2019000 Pence per share \u00a3\u2019000 Pence per share Revenue earnings 36,264 5.85 29,459 4.92 Capital earnings (42,836) (6.91) 19,638 3.28 Total earnings (6,572) (1.06) 49,097 8.20 Average number of shares in issue 620,237,346 599,093,808 There were no dilutive shares or potentially dilutive shares in issue. EPRA is an industry body which issues best practice reporting guidelines for financial disclosures by public real estate companies and the Group reports an EPRA NAV quarterly. EPRA has issued best practice recommendations for the calculation of certain figures which are included below. Other EPRA measures are included in the EPRA Performance Measures on pages 98 and 99. The EPRA earnings are arrived at by adjusting for the revaluation movements on investment properties and other items of a capital nature and represents the revenue earned by the Group. The Group\u2019s specific adjusted EPRA earnings adjusts the EPRA earnings for rental income arising from recognising guaranteed rental review uplifts and for development interest received from developers in relation to monies advanced under forward fund agreements which, in the Group\u2019s IFRS financial statements, is required to be offset against the book cost of the property under development. The Board believes that the Group\u2019s specific adjusted EPRA earnings represents the underlying performance measure appropriate for the Group\u2019s business model as it illustrates the underlying revenue stream and costs generated by the Group\u2019s property portfolio. The reconciliations are provided in the table below: Year ended 30 June 2023 \u00a3\u2019000 Year ended 30 June 2022 \u00a3\u2019000 Earnings per IFRS Consolidated Statement of Comprehensive Income (6,572) 49,097 Adjusted for gains on investment properties realised (575) \u2013 Adjusted for revaluations of investment properties 54,021 (5,553) Adjusted for revaluations of properties held for sale \u2013 7 Adjusted for finance and transaction costs on the interest rate cap and other capital items 698 (3,877) EPRA earnings 47,572 39,674 Adjusted for rental income arising from recognising guaranteed rent review uplifts (11,308) (10,215) Adjusted for development interest under forward fund agreements 952 783 Group specific adjusted EPRA earnings 37,216 30,242 Earnings per share (\u2018EPS\u2019) (pence per share) EPS per IFRS Consolidated Statement of Comprehensive Income (1.06) 8.20 EPRA EPS 7.67 6.62 Group specific adjusted EPRA EPS 6.00 5.05 Net Asset Value per share The Group\u2019s Net Asset Value per ordinary share of 105.6 pence (2022: 112.7 pence) is based on equity shareholders\u2019 funds of \u00a3654,808,000 (2022: \u00a3698,767,000) and on 620,237,346 (2022: 620,237,346) ordinary shares, being the number of shares in issue at the year-end. The EPRA best practice recommendations include a set of EPRA NAV metrics that are arrived at by adjusting the net asset value calculated under International Financial Reporting Standards (\u2018IFRS\u2019) to provide stakeholders with what EPRA believe to be the most relevant information on the fair value of the assets and liabilities of a real estate investment company, under different scenarios. The three EPRA NAV metrics are: \u2013 EPRA Net Reinstatement Value (\u2018NRV\u2019): Assumes that entities never sell assets and aims to represent the value required to rebuild the entity. The objective is to highlight the value of net assets on a long-term basis. Assets and liabilities that are not expected to crystallise  in normal circumstances, such as the fair value movements on financial derivatives, are excluded and the costs of recreating the Group through investment markets, such as property acquisition costs and taxes, are included. \u2013 EPRA Net Tangible Assets (\u2018NTA\u2019): Assumes that entities buy and sell assets, thereby crystallising certain levels of unavoidable deferred tax. Given the Group\u2019s REIT status, it is not expected that significant deferred tax will be applicable to the Group. \u2013 EPRA Net Disposal Value (\u2018NDV\u2019): Represents the shareholders\u2019 value under a disposal scenario, where deferred tax, financial instruments and certain other adjustments are calculated to the full extent of their liability, net of any resulting tax. At 30 June 2023, the Group held all its material balance sheet items at fair value, or at a value considered to be a close approximation to fair value, in its financial statements apart from its fixed-rate debt facilities where the fair value is estimated to be lower than the nominal value. See Note 13 for further details  on the Group\u2019s loan facilities. 2023 EPRA NRV \u00a3\u2019000 2023 EPRA NTA \u00a3\u2019000 2023 EPRA NDV \u00a3\u2019000 2022 EPRA NRV \u00a3\u2019000 2022 EPR A NTA \u00a3\u2019000 2022 EPRA NDV \u00a3\u2019000 IFRS NAV per financial statements 654,808 654,808 654,808 698,767 698,767 698,767 Fair value of interest rate derivatives (6,905) (6,905) \u2013 (2,284) (2,284) \u2013 Fair value of loans \u2013 \u2013 39,672 \u2013 \u2013 22,257 Estimated purchasers\u2019 costs 57,461 \u2013 \u2013 60,225 \u2013 \u2013 EPRA net assets  705,364 647,903 694,480 756,708 696,483 721,024 EPRA net assets (pence per share) 113.7 104.5 112.0 122.0 112.3 116.2",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-371": {
   "value": "8. Earnings per share and Net Asset Value per share Earnings per share Year ended 30 June 2023 Year ended 30 June 2022 \u00a3\u2019000 Pence per share \u00a3\u2019000 Pence per share Revenue earnings 36,264 5.85 29,459 4.92 Capital earnings (42,836) (6.91) 19,638 3.28 Total earnings (6,572) (1.06) 49,097 8.20 Average number of shares in issue 620,237,346 599,093,808 There were no dilutive shares or potentially dilutive shares in issue. EPRA is an industry body which issues best practice reporting guidelines for financial disclosures by public real estate companies and the Group reports an EPRA NAV quarterly. EPRA has issued best practice recommendations for the calculation of certain figures which are included below. Other EPRA measures are included in the EPRA Performance Measures on pages 98 and 99. The EPRA earnings are arrived at by adjusting for the revaluation movements on investment properties and other items of a capital nature and represents the revenue earned by the Group. The Group\u2019s specific adjusted EPRA earnings adjusts the EPRA earnings for rental income arising from recognising guaranteed rental review uplifts and for development interest received from developers in relation to monies advanced under forward fund agreements which, in the Group\u2019s IFRS financial statements, is required to be offset against the book cost of the property under development. The Board believes that the Group\u2019s specific adjusted EPRA earnings represents the underlying performance measure appropriate for the Group\u2019s business model as it illustrates the underlying revenue stream and costs generated by the Group\u2019s property portfolio. The reconciliations are provided in the table below: Year ended 30 June 2023 \u00a3\u2019000 Year ended 30 June 2022 \u00a3\u2019000 Earnings per IFRS Consolidated Statement of Comprehensive Income (6,572) 49,097 Adjusted for gains on investment properties realised (575) \u2013 Adjusted for revaluations of investment properties 54,021 (5,553) Adjusted for revaluations of properties held for sale \u2013 7 Adjusted for finance and transaction costs on the interest rate cap and other capital items 698 (3,877) EPRA earnings 47,572 39,674 Adjusted for rental income arising from recognising guaranteed rent review uplifts (11,308) (10,215) Adjusted for development interest under forward fund agreements 952 783 Group specific adjusted EPRA earnings 37,216 30,242 Earnings per share (\u2018EPS\u2019) (pence per share) EPS per IFRS Consolidated Statement of Comprehensive Income (1.06) 8.20 EPRA EPS 7.67 6.62 Group specific adjusted EPRA EPS 6.00 5.05 Net Asset Value per share The Group\u2019s Net Asset Value per ordinary share of 105.6 pence (2022: 112.7 pence) is based on equity shareholders\u2019 funds of \u00a3654,808,000 (2022: \u00a3698,767,000) and on 620,237,346 (2022: 620,237,346) ordinary shares, being the number of shares in issue at the year-end. The EPRA best practice recommendations include a set of EPRA NAV metrics that are arrived at by adjusting the net asset value calculated under International Financial Reporting Standards (\u2018IFRS\u2019) to provide stakeholders with what EPRA believe to be the most relevant information on the fair value of the assets and liabilities of a real estate investment company, under different scenarios. The three EPRA NAV metrics are: \u2013 EPRA Net Reinstatement Value (\u2018NRV\u2019): Assumes that entities never sell assets and aims to represent the value required to rebuild the entity. The objective is to highlight the value of net assets on a long-term basis. Assets and liabilities that are not expected to crystallise  in normal circumstances, such as the fair value movements on financial derivatives, are excluded and the costs of recreating the Group through investment markets, such as property acquisition costs and taxes, are included. \u2013 EPRA Net Tangible Assets (\u2018NTA\u2019): Assumes that entities buy and sell assets, thereby crystallising certain levels of unavoidable deferred tax. Given the Group\u2019s REIT status, it is not expected that significant deferred tax will be applicable to the Group. \u2013 EPRA Net Disposal Value (\u2018NDV\u2019): Represents the shareholders\u2019 value under a disposal scenario, where deferred tax, financial instruments and certain other adjustments are calculated to the full extent of their liability, net of any resulting tax. At 30 June 2023, the Group held all its material balance sheet items at fair value, or at a value considered to be a close approximation to fair value, in its financial statements apart from its fixed-rate debt facilities where the fair value is estimated to be lower than the nominal value. See Note 13 for further details  on the Group\u2019s loan facilities. 2023 EPRA NRV \u00a3\u2019000 2023 EPRA NTA \u00a3\u2019000 2023 EPRA NDV \u00a3\u2019000 2022 EPRA NRV \u00a3\u2019000 2022 EPR A NTA \u00a3\u2019000 2022 EPRA NDV \u00a3\u2019000 IFRS NAV per financial statements 654,808 654,808 654,808 698,767 698,767 698,767 Fair value of interest rate derivatives (6,905) (6,905) \u2013 (2,284) (2,284) \u2013 Fair value of loans \u2013 \u2013 39,672 \u2013 \u2013 22,257 Estimated purchasers\u2019 costs 57,461 \u2013 \u2013 60,225 \u2013 \u2013 EPRA net assets  705,364 647,903 694,480 756,708 696,483 721,024 EPRA net assets (pence per share) 113.7 104.5 112.0 122.0 112.3 116.2",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfNetAssetValueAttributableToUnitholdersExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-346": {
   "value": "9. Investment properties Freehold and leasehold properties As at 30 June 2023 \u00a3\u2019000 As at 30 June 2022 \u00a3\u2019000 Opening market value 911,596 677,525 Opening fixed or guaranteed rent reviews and lease incentives (56,705) (47,919) Opening performance payments 2,800 1,550 Opening carrying value 857,691 631,156 Disposals \u2013  proceeds (26,728) \u2013    \u2013  gain on sale 6,088 \u2013 Purchases and performance payments 23,494 199,869 Transfer from properties held for sale \u2013 6,830 Acquisition costs capitalised 273 9,671 Acquisition costs written off (273) (9,671) Unrealised gain realised during the year (5,513) \u2013 Revaluation movement \u2013 gains 3,645 43,234 Revaluation movement \u2013 losses (43,877) (15,862) Movement in market value (42,891) 234,071 Fixed or guaranteed rent reviews and lease incentives derecognised on disposal or re-tenanting 1,671 3,362 Movement in fixed or guaranteed rent reviews and lease incentives (13,516) (12,148) Movement in performance payments (2,800) 1,250 Movement in carrying value (57,536) 226,535 Closing market value 868,705 911,596 Closing fixed or guaranteed rent reviews and lease incentives (68,550) (56,705) Closing performance payments (see Note 18) \u2013 2,800 Closing carrying value 800,155 857,691 Changes in the valuation of investment properties Year ended 30 June 2023 \u00a3\u2019000 Year ended 30 June 2022 \u00a3\u2019000 Gain on sale of investment properties 6,088 \u2013 Unrealised gain realised during the year (5,513) \u2013 Gain on sale of investment properties realised 575 \u2013 Revaluation movement (40,232) 27,372 Acquisition costs written off (273) (9,671) Movement in lease incentives (2,208) (1,933) Movement in fixed or guaranteed rent reviews (11,308) (10,215) (Losses)/gains on revaluation of investment properties (53,446) 5,553 The investment properties can be analysed as follows: As at 30 June 2023 \u00a3\u2019000 As at 30 June 2022 \u00a3\u2019000 Standing assets 851,305 892,336 Developments under forward fund agreements 17,400 19,260 Closing market value 868,705 911,596 The properties were valued at \u00a3868,705,000 (2022: \u00a3911,596,000) by Colliers International Healthcare Property Consultants Limited (\u2018Colliers\u2019), in their capacity as external valuers. The valuation was undertaken in accordance with the RICS Valuation \u2013 Global Standards, incorporating the International Valuation Standards (the \u2018Red Book Global\u2019, 31 January 2022) issued by the Royal Institution of Chartered Surveyors (\u2018RICS\u2019) on the basis of Market Value, supported by reference to market evidence of transaction prices for similar properties. Colliers has recent experience in the location and category of the investment properties being valued. Market Value represents the estimated amount for which an asset or liability should exchange on the valuation date between a willing buyer and a willing seller in an arm\u2019s length transaction, after proper marketing where the parties had each acted knowledgeably, prudently and without compulsion. The quarterly property valuations are reviewed by the Board at each Board meeting. The fair value of the properties after adjusting for the movement in the fixed or guaranteed rent reviews and lease incentives was \u00a3800,155,000 (2022: \u00a3857,691,000). The adjustment consisted of \u00a359,378,000 (2022: \u00a348,802,000) relating to fixed or guaranteed rent reviews and \u00a39,172,000 (2022: \u00a37,903,000) of accrued income relating to the recognition of rental income over rent free periods subsequently amortised over the life of the lease, which are both separately recorded in the accounts as non-current or current assets within \u2018trade and other receivables\u2019 (see Note 10). An adjustment is also made to reflect the amount by which the portfolio value is expected to increase if the performance payments recognised in \u2018trade and other payables\u2019 are paid and the passing rent at the relevant property increased accordingly (see Notes 14 and 18). The total purchases in the year to 30 June 2023, excluding the performance payments recognised in the prior year, were \u00a320,694,000 (2022: \u00a3201,119,000). All leasehold properties are carried at fair value rather than amortised over the term of the lease. The same valuation criteria are therefore applied to leasehold as freehold properties. Other than one property where the leasehold expires in 2265, all leasehold properties have more than 800 years remaining on the lease term. The Group\u2019s investment properties are valued by Colliers on a quarterly basis. The valuation methodology used is the yield model, which is  a consistent basis for the valuation of investment properties within the healthcare industry. This model has regard to the current investment market and evidence of investor interest in properties with income streams secured on healthcare businesses. On an asset-specific basis,  the valuer makes an assessment of: the quality of the asset; recent and current performance of the asset; and the financial position and performance of the tenant operator. This asset specific information is used alongside a review of comparable transactions in the market  and a yield is applied to the asset which, along with the contracted rental level, is used to derive a market value. The real estate investment and occupier markets are currently in a state of transition as they begin to align themselves with the sustainable development goals of government and the new generation of real estate users. Colliers are mindful of the potential impacts ESG may have  on capital and rental valuations and have considered the guidance provided by the RICS and VPGA 8 of the Red Book. Specific climate-related risks, such as a reasonably foreseeable increase in the risk of site or coastal flooding, are reflected in the property valuations. However, Colliers have not undertaken sustainability audits and are not qualified to do so as valuers. Therefore the external valuations only explicitly reflect immediate sustainability/resilience capital costs where technical information relating to the same has been made available, namely in respect of upgrading the properties to meet Minimum Energy Efficiency Standard regulations and flood prevention. The Group is required to classify fair value measurements of its investment properties using a fair value hierarchy, in accordance with IFRS 13 \u2018Fair Value Measurement\u2019. This hierarchy reflects the subjectivity of the inputs used, and has the following levels: \u2013 Level 1: unadjusted quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date; \u2013 Level 2: observable inputs other than quoted prices included within level 1; \u2013 Level 3: use of inputs that are not based on observable market data. In determining what level of the fair value hierarchy to classify the Group\u2019s investments within, the Directors have considered the content and conclusion of the position paper on IFRS 13 prepared by the European Public Real Estate Association (\u2018EPRA\u2019), the representative body of the publicly listed real estate industry in Europe. This paper concludes that, even in the most transparent and liquid markets, it is likely that valuers of investment property will use one or more significant unobservable inputs or make at least one significant adjustment to an observable input, resulting in the vast majority of investment properties being classified as level 3. Observable market data is considered to be that which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. In arriving at the valuation Colliers make adjustments to observable data of similar properties and transactions to determine the fair value of a property and this involves the use of considerable judgement. Considering the Group\u2019s specific valuation process, industry guidance, and the level of judgement required in the valuation process, the Directors believe it appropriate to classify the Group\u2019s investment properties within level 3 of the fair value hierarchy. The Group\u2019s investment properties, which are all care homes, are considered to be a single class of assets. The weighted average net initial yield (\u2018NIY\u2019) on these assets, as measured by the EPRA topped up NIY, is 6.2 per cent. The yield on the majority of the individual assets ranges from 5.5 per cent to 8.7 per cent. There have been no changes to the valuation technique used through the period, nor have there been any transfers between levels. The key unobservable inputs made in determining the fair values are: \u2013 Contracted rental level: the rent payable under the lease agreement at the date of valuation or, where applicable, on expiry of the rent free period; and \u2013 Yield: the yield is defined as the initial net income from a property at the date of valuation, expressed as a percentage of the gross purchase price including the costs of purchase. The contracted rental level and yield are not directly correlated although they may be influenced by similar factors. Rent is set at a long-term, supportable level and is likely to be influenced by property-specific matters. The yield also reflects market sentiment and the strength of the covenant provided by the tenant with a stronger covenant attracting a lower yield. The lease agreements on the properties held within the Group\u2019s property portfolio generally allow for annual increases in the contracted rental level in line with inflation, within a cap and a collar. An increase of 1.0 per cent in the contracted rental level will increase the fair value  of the portfolio, and consequently the Group\u2019s reported income from unrealised gains on investments, by \u00a38,687,000 (2022: \u00a39,116,000);  an equal and opposite movement would have decreased net assets and decreased the Group\u2019s income by the same amount. A decrease of 0.25 per cent in the yield applied to the portfolio will increase the fair value of the portfolio by \u00a337,940,000 (2022: \u00a340,729,000), and consequently increase the Group\u2019s reported income from unrealised gains on investments. An increase of 0.25 per cent in the net initial yield will decrease the fair value of the portfolio by \u00a335,025,000 (2022: \u00a337,388,000) and reduce the Group\u2019s income",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfInvestmentPropertyExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-347": {
   "value": "10. Trade and other receivables Non-current trade and other receivables As at 30 June 2023 \u00a3\u2019000 As at 30 June 2022 \u00a3\u2019000 Fixed rent reviews 59,378 48,802 Rental deposits held in escrow for tenants 8,093 7,145 Lease incentives 8,902 7,704 Total 76,373 63,651 Current trade and other receivables As at 30 June 2023 \u00a3\u2019000 As at 30 June 2022 \u00a3\u2019000 Cash held in escrow for property purchases 4,295 \u2013 Lease incentives 270 199 VAT recoverable 667 1,387 Accrued income \u2013 rent receivable 1,088 906 Accrued development interest under forward fund agreements 1,010 452 Other debtors and prepayments 2,129 2,605 Total 9,459 5,549 At the year-end, trade and other receivables include a fixed rent review debtor of \u00a359,378,000 (2022: \u00a348,802,000) which represents the effect of recognising guaranteed rental uplifts on a straight line basis over the lease term and \u00a39,172,000 (2022: \u00a37,903,000) of accrued income relating to the recognition of rental income over rent free periods subsequently amortised over the life of the lease",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-348": {
   "value": "11. Investment in subsidiary undertakings The Group included 49 subsidiary companies as at 30 June 2023 (30 June 2022: 57). All subsidiary companies were wholly owned, either directly or indirectly, by the Company and, from the date of acquisition onwards, the principal activity of each company within the Group was to act as an investment and property company. Other than one subsidiary incorporated in Jersey, two subsidiaries incorporated in Gibraltar and two subsidiaries incorporated in Luxembourg, all subsidiaries are incorporated within the United Kingdom. The Group did not incorporate or acquire any new subsidiaries during the year. At 30 June 2022, the Group included eight companies which had been acquired as part of previous corporate acquisitions and which, having remained dormant throughout the prior year, were dissolved during the year ended 30 June 2023",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-349": {
   "value": "12. Cash and cash equivalents All cash balances at the year-end were held in cash, current accounts or deposit accounts. As at 30 June 2023 \u00a3\u2019000 As at 30 June 2022 \u00a3\u2019000 Cash at bank and in hand 12,745 34,020 Short-term deposits 2,621 463 Total 15,366 34,483",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-350": {
   "value": "13. Loans As at 30 June 2023 \u00a3\u2019000 As at 30 June 2022 \u00a3\u2019000 Principal amount outstanding 230,000 234,750 Set-up costs (4,520) (4,315) Amortisation of set-up costs 1,571 948 Total 227,051 231,383 In November 2020, the Group entered into a \u00a370,000,000 committed term loan and revolving credit facility with the Royal Bank of Scotland plc (\u2018RBS\u2019) which is repayable in November 2025. Interest accrues on the bank loan at a variable rate, based on SONIA plus margin and mandatory lending costs, and is payable quarterly. The margin is 2.18 per cent per annum on \u00a350,000,000 of the facility and 2.33 per cent per annum on the remaining \u00a320,000,000 revolving credit facility, both for the duration of the loan. A non-utilisation fee of 1.13 per cent per annum is payable on the first \u00a320,000,000 of any undrawn element of the facility, reducing to 1.05 per cent per annum thereafter. As at 30 June 2023, the Group had drawn \u00a330,000,000 under this facility (2022: \u00a350,000,000). In November 2020, the Group entered into a \u00a3100,000,000 revolving credit facility with HSBC Bank plc (\u2018HSBC\u2019) which is repayable in November 2025. Interest accrues on the bank loan at a variable rate, based on SONIA plus margin and mandatory lending costs, and is payable quarterly. The margin is 2.17 per cent per annum for the duration of the loan and a non-utilisation fee of 0.92 per cent per annum is payable on any undrawn element of the facility. As at 30 June 2023, the Group had drawn \u00a350,000,000 under this facility (2022: \u00a334,750,000). In January 2020 and November 2021, the Group entered into committed term loan facilities with Phoenix Group of \u00a350,000,000 and \u00a337,250,000, respectively. Both these facilities are repayable on 12 January 2032. The Group has a further committed term loan facility with Phoenix Group of \u00a362,750,000 which is repayable on 12 January 2037. Interest accrues on these three loans at aggregate annual fixed rates of interest of 3.28 per cent, 3.13 per cent and 3.14 per cent, respectively and is payable quarterly. As at 30 June 2023, the Group had drawn \u00a3150,000,000 under these facilities (2022: \u00a3150,000,000). The following interest rate derivatives were in place during the year ended 30 June 2023: Notional Value Starting Date Ending Date Interest paid Interest received Counterparty 30,000,000 5 November 2020 5 November 2025 0.30% Daily compounded SONIA (floor at -0.08%) RBS 50,000,000 1 November 2022 5 November 2025 nil Daily compounded SONIA above 3.0% cap HSBC The Group paid a premium of \u00a32,577,000, inclusive of transaction costs of \u00a3169,000, on entry into the \u00a350,000,000 interest rate cap. At 30 June 2023, inclusive of the interest rate derivatives, the interest rate on \u00a3230,000,000 of the Group\u2019s borrowings has been capped, including the amortisation of loan arrangement costs, at an all-in rate of 3.70 per cent per annum until at least 5 November 2025. The remaining \u00a390,000,000 of debt, which was undrawn at 30 June 2023, would, if fully drawn, carry interest at a variable rate equal to daily compounded SONIA plus a weighted average lending margin, including the amortisation of loan arrangement costs, of 2.46 per cent per annum. The aggregate fair value of the interest rate derivatives held at 30 June 2023 was an asset of \u00a36,905,000 (2022: \u00a32,284,000). The Group categorises all interest rate derivatives as level 2 in the fair value hierarchy (see Note 9 for further explanation of the fair value hierarchy). At 30 June 2023, the nominal value of the Group\u2019s loans equated to \u00a3230,000,000 (2022: \u00a3234,750,000). Excluding the interest rate derivatives referred to above, the fair value of these loans, based on a discounted cashflow using the market rate on the relevant treasury plus an estimated margin based on market conditions at 30 June 2023, totalled, in aggregate, \u00a3190,328,000 (2022: \u00a3212,493,000). The payment required to redeem the loans in full, incorporating the terms of the Spens clause in relation to the Phoenix Group facilities, would have been \u00a3209,898,000 (2022: \u00a3239,728,000). The loans are categorised as level 3 in the fair value hierarchy. The RBS loan is secured by way of a fixed and floating charge over the majority of the assets of the THR Number One plc Group (\u2018THR1 Group\u2019) which consists of THR1 and its five subsidiaries. The Phoenix Group loans of \u00a350,000,000 and \u00a337,250,000 are secured by way of a fixed and floating charge over the majority of the assets of the THR Number 12 plc Group (\u2018THR12 Group\u2019) which consists of THR12 and its eight subsidiaries. The Phoenix Group loan of \u00a362,750,000 is secured by way of a fixed and floating charge over the majority of the assets of THR Number 43 plc (\u2018THR43\u2019). The HSBC loan is secured by way of a fixed and floating charge over the majority of the assets of the THR Number 15 plc Group (\u2018THR15 Group\u2019) which consists of THR15 and its 18 subsidiaries. In aggregate, the Group has granted a fixed charge over properties with a market value of \u00a3762,100,000 as at 30 June 2023 (2022: \u00a3795,949,000). Under the covenants related to the loans, the Group is to ensure that: \u2013 the loan to value percentage for each of THR1 Group and THR15 Group does not exceed 50 per cent; \u2013 the loan to value percentage for THR12 Group and THR43 does not exceed 60 per cent; \u2013 the interest cover for THR1 Group is greater than 225 per cent (30 June 2022: 300 per cent) on any calculation date; \u2013 the interest cover for THR15 Group is greater than 200 per cent (30 June 2022: 300 per cent) on any calculation date; and \u2013 the debt yield for each of THR12 Group and THR43 is greater than 10 per cent on any calculation date. During the year ended 30 June 2023, the Group entered into agreements with HSBC and RBS to relax the interest cover covenants on the relevant loans with effect from 1 January 2023. All other significant terms of the facilities remained unchanged. All loan covenants have been complied with during the year. Analysis of net debt: Cash and cash equivalents 2023 \u00a3\u2019000 Borrowing 2023 \u00a3\u2019000 Net debt 2023 \u00a3\u2019000 Cash and cash equivalents 2022 \u00a3\u2019000 Borrowing 2022 \u00a3\u2019000 Net debt 2022 \u00a3\u2019000 Opening balance 34,483 (231,383) (196,900) 21,106 (127,904) (106,798) Cash flows (19,117) 4,955 (14,162) 13,377 (102,911) (89,534) Non-cash flows \u2013 (623) (623) \u2013 (568) (568) Closing balance as at 30 June 15,366 (227,051) (211,685) 34,483 (231,383) (196,900)",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfBorrowingsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-351": {
   "value": "14. Trade and other payables Non-current trade and other payables As at 30 June 2023 \u00a3\u2019000 As at 30 June 2022 \u00a3\u2019000 Rental deposits 8,093 7,145 Total 8,093 7,145 Current trade and other payables As at 30 June 2023 \u00a3\u2019000 As at 30 June 2022 \u00a3\u2019000 Rental income received in advance 8,239 8,390 Property acquisition and development costs accrued 3,875 8,892 Performance payments \u2013 2,800 Investment Manager\u2019s fees payable 1,835 1,895 Interest payable 1,992 1,762 Other payables 2,365 2,624 Total 18,306 26,363 The Group\u2019s payment policy is to ensure settlement of supplier invoices in accordance with stated terms.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-352": {
   "value": "15. Share capital Allotted, called-up and fully paid ordinary shares of \u00a30.01 each Number of shares \u00a3\u2019000 Balance as at 30 June 2022 and 30 June 2023 620,237,346 6,202 Under the Company\u2019s Articles of Association, the Company may issue an unlimited number of ordinary shares. Ordinary shareholders are entitled to all dividends declared by the Company and to all of the Company\u2019s assets after repayment of its borrowings and ordinary creditors. Ordinary shareholders have the right to vote at meetings of the Company. All ordinary shares carry equal voting rights. During the year to 30 June 2023, the Company did not issue any ordinary shares (2022: issued 108,695,652 ordinary shares of \u00a30.01 each raising gross proceeds of \u00a3125,000,000). The Company did not repurchase any ordinary shares into treasury (2022: nil) or resell any ordinary shares from treasury (2022: nil). At 30 June 2023, the Company did not hold any shares in treasury (2022: nil). Capital management The Group\u2019s capital is represented by the share capital, share premium, merger reserve, distributable reserve, hedging reserve, capital reserve, revenue reserve and long-term borrowings. The Group is not subject to any externally-imposed capital requirements, other than the financial covenants on its loan facilities as detailed in Note 13. The capital of the Group is managed in accordance with its investment policy, in pursuit of its investment objective. Capital risk management The objective of the Group is to provide ordinary shareholders with an attractive level of income together with the potential for income and capital growth from investing in a diversified portfolio of freehold and long leasehold care homes that are let to care home operators; and other healthcare assets in the UK. The Board has responsibility for ensuring the Group\u2019s ability to continue as a going concern. This involves the ability to borrow monies in  the short and long term; and pay dividends out of reserves, all of which are considered and approved by the Board on a regular basis. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders, issue new shares or buyback shares for cancellation or for holding in treasury. The Company may also increase or decrease its level of long- term borrowings. Where ordinary shares are held in treasury these are available to be sold to meet on-going market demand. The ordinary shares will be  sold only at a premium to the prevailing NAV per share. The net proceeds of any subsequent sales of shares out of treasury will provide the Company with additional capital to enable it to take advantage of investment opportunities in the market and make further investments in accordance with the Company\u2019s investment policy and within its appraisal criteria. Holding shares in treasury for this purpose assists the Company in matching its on-going capital requirements to its investment opportunities and therefore reduces the negative effect of holding excess cash on its balance sheet over the longer term. No changes were made in the capital management objectives, policies or processes during the year.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-372": {
   "value": "15. Share capital Allotted, called-up and fully paid ordinary shares of \u00a30.01 each Number of shares \u00a3\u2019000 Balance as at 30 June 2022 and 30 June 2023 620,237,346 6,202 Under the Company\u2019s Articles of Association, the Company may issue an unlimited number of ordinary shares. Ordinary shareholders are entitled to all dividends declared by the Company and to all of the Company\u2019s assets after repayment of its borrowings and ordinary creditors. Ordinary shareholders have the right to vote at meetings of the Company. All ordinary shares carry equal voting rights. During the year to 30 June 2023, the Company did not issue any ordinary shares (2022: issued 108,695,652 ordinary shares of \u00a30.01 each raising gross proceeds of \u00a3125,000,000). The Company did not repurchase any ordinary shares into treasury (2022: nil) or resell any ordinary shares from treasury (2022: nil). At 30 June 2023, the Company did not hold any shares in treasury (2022: nil). ",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-373": {
   "value": "Capital management The Group\u2019s capital is represented by the share capital, share premium, merger reserve, distributable reserve, hedging reserve, capital reserve, revenue reserve and long-term borrowings. The Group is not subject to any externally-imposed capital requirements, other than the financial covenants on its loan facilities as detailed in Note 13. The capital of the Group is managed in accordance with its investment policy, in pursuit of its investment objective. Capital risk management The objective of the Group is to provide ordinary shareholders with an attractive level of income together with the potential for income and capital growth from investing in a diversified portfolio of freehold and long leasehold care homes that are let to care home operators; and other healthcare assets in the UK. The Board has responsibility for ensuring the Group\u2019s ability to continue as a going concern. This involves the ability to borrow monies in  the short and long term; and pay dividends out of reserves, all of which are considered and approved by the Board on a regular basis. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders, issue new shares or buyback shares for cancellation or for holding in treasury. The Company may also increase or decrease its level of long- term borrowings. Where ordinary shares are held in treasury these are available to be sold to meet on-going market demand. The ordinary shares will be  sold only at a premium to the prevailing NAV per share. The net proceeds of any subsequent sales of shares out of treasury will provide the Company with additional capital to enable it to take advantage of investment opportunities in the market and make further investments in accordance with the Company\u2019s investment policy and within its appraisal criteria. Holding shares in treasury for this purpose assists the Company in matching its on-going capital requirements to its investment opportunities and therefore reduces the negative effect of holding excess cash on its balance sheet over the longer term. No changes were made in the capital management objectives, policies or processes during the year.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-384": {
   "value": "16. Financial instruments Consistent with its objective, the Group holds UK care home property investments. In addition, the Group\u2019s financial instruments comprise cash, loans and receivables and payables that arise directly from its operations. The Group\u2019s exposure to derivative instruments consists of interest rate swaps and interest rate caps used to fix the interest rate on the Group\u2019s variable rate borrowings. The Group is exposed to various types of risk that are associated with financial instruments. The most important types are credit risk,  liquidity risk, interest rate risk and market price risk. There is no foreign currency risk as all assets and liabilities of the Group are maintained  in pounds sterling. The Board reviews and agrees policies for managing the Group\u2019s risk exposure. These policies are summarised below and have remained unchanged for the year under review. These disclosures include, where appropriate, consideration of the Group\u2019s investment properties which, whilst not constituting financial instruments as defined by IFRS, are considered by the Board to be integral to the Group\u2019s overall risk exposure. Credit risk Credit risk is the risk that an issuer or counterparty will be unable or unwilling to meet a commitment that it has entered into with the Group.  At the reporting date, the Group\u2019s financial assets exposed to credit risk amounted to \u00a323,517,000 (2022: \u00a338,996,000), consisting of cash  of \u00a315,366,000 (2022: \u00a334,483,000), cash held in escrow for property purchases of \u00a34,295,000 (2022: \u00a3nil), net rent receivable of \u00a31,088,000 (2022: \u00a3906,000), VAT recoverable of \u00a3667,000 (2022: \u00a31,387,000), accrued development interest of \u00a31,010,000 (2022: \u00a3452,000) and other debtors of \u00a31,091,000 (2022: \u00a31,768,000). In the event of default by a tenant if it is in financial difficulty or otherwise unable to meet its obligations under the lease, the Group will  suffer a rental shortfall and incur additional expenses until the property is relet. These expenses could include legal and surveyor\u2019s costs in reletting, maintenance costs, insurances, rates and marketing costs and may have a material adverse impact on the financial condition and performance of the Group and/or the level of dividend cover. The Group may also require to provide rental incentives to the incoming tenant. The Board receives regular reports on concentrations of risk and any tenants in arrears. The Investment Manager monitors such reports in order to anticipate, and minimise the impact of, defaults by occupational tenants. The expected credit risk in relation to tenants is an inherent element of the due diligence considered by the Investment Manager on all property transactions with an emphasis being placed on ensuring that initial rents are set at a sustainable level. The risk is further mitigated by rental deposits or guarantees where considered appropriate. The majority of rental income is received in advance. As at 30 June 2023, the Group had recognised a credit loss allowance totalling \u00a31,972,000 against a gross rent receivable balance of \u00a32,496,000 and gross loans to tenants totalling \u00a3989,000. As at 30 June 2022, the gross receivable was \u00a38,496,000, of which \u00a31,280,000 was subsequently recovered, \u00a35,117,000 was written off and \u00a32,099,000 is still outstanding. There were no other financial assets which were either past due or considered impaired at 30 June 2023 (2022: nil). All of the Group\u2019s cash is placed with financial institutions with a long-term credit rating of BBB or better. Bankruptcy or insolvency of such financial institutions may cause the Group\u2019s ability to access cash placed on deposit to be delayed, limited or lost. Should the credit quality  or the financial position of the banks currently employed significantly deteriorate, cash holdings would be moved to another bank. Should the Group hold significant cash balances for an extended period, then counterparty risk will be spread, by placing cash across different financial institutions. At 30 June 2023 the Group held \u00a315.2 million (2022: \u00a334.5 million) with The Royal Bank of Scotland plc and \u00a30.2 million (2022: \u00a3nil) with HSBC Bank plc. Given the credit quality of the counterparties used, no credit loss allowance is recognised against cash balances as it is considered to be immaterial. Liquidity risk Liquidity risk is the risk that the Group will encounter difficulties in realising assets or otherwise raising funds to meet financial commitments. The Group\u2019s investments comprise UK care homes. Property and property-related assets in which the Group invests are not traded in an organised public market and may be illiquid. As a result, the Group may not be able to liquidate quickly its investments in these properties  at an amount close to their fair value in order to meet its liquidity requirements. The Group\u2019s liquidity risk is managed on an on-going basis by the Investment Manager and monitored on a quarterly basis by the Board.  In order to mitigate liquidity risk the Group aims to have sufficient cash balances (including the expected proceeds of any property sales)  to meet its obligations for a period of at least twelve months. At the reporting date, the maturity of the financial assets was: Financial assets as at 30 June 2023 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Cash 15,366 \u2013 \u2013 \u2013 \u2013 15,366 Rental deposits held in escrow for tenants \u2013 \u2013 \u2013 \u2013 8,093 8,093 Cash held in escrow for property purchases 4,295 \u2013 \u2013 \u2013 \u2013 4,295 Other debtors 3,856 \u2013 \u2013 \u2013 \u2013 3,856 Total 23,517 \u2013 \u2013 \u2013 8,093 31,610 Financial assets as at 30 June 2022 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Cash 34,483 \u2013 \u2013 \u2013 \u2013 34,483 Rental deposits held in escrow for tenants \u2013 \u2013 \u2013 \u2013 7,145 7,145 Other debtors 4,513 \u2013 \u2013 \u2013 \u2013 4,513 Total 38,996 \u2013 \u2013 \u2013 7,145 46,141 At the reporting date, the maturity of the financial liabilities was: Financial liabilities as at 30 June 2023 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Loans and interest rate derivatives 2,269 6,757 9,001 95,821 176,747 290,595 Rental deposits \u2013 \u2013 \u2013 \u2013 8,093 8,093 Other payables 10,067 \u2013 \u2013 \u2013 \u2013 10,067 Total 12,336 6,757 9,001 95,821 184,840 308,755 Financial liabilities as at 30 June 2022 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Loans and interest rate derivatives 2,046 6,072 8,140 101,890 181,533 299,681 Rental deposits \u2013 \u2013 \u2013 \u2013 7,145 7,145 Other payables 17,973 \u2013 \u2013 \u2013 \u2013 17,973 Total 20,019 6,072 8,140 101,890 188,678 324,799 The total amount due under the loan facilities includes the expected hedged interest payments due under both the loan and interest rate derivatives combined (see Note 13 for further details) assuming that both the drawn element of the loans and the notional value of the interest rate derivatives remain unchanged from 30 June 2023 (30 June 2022) until the repayment date of the relevant loan and expiry date of the related interest rate derivative. The interest rate on any unhedged element of the loans is based on the rate of SONIA at 30 June 2023 (30 June 2022) plus the relevant lending margin. The commitment fee payable on the undrawn element of any facility is included, where applicable . Interest rate risk Some of the Company\u2019s financial instruments are interest-bearing. Interest-rate risk is the risk that future cash flows will change adversely  as a result of changes in market interest rates. The Group\u2019s policy is to hold cash in variable rate or short-term fixed rate bank accounts. At 30 June 2023, interest was being received on cash at a weighted average variable rate of nil (2022: nil). Exposure varies throughout the period as a consequence of changes in the composition of the net assets of the Group arising out of the investment and risk management policies. These balances expose the Group to cash flow interest rate risk as the Group\u2019s income and operating cash flows will be affected by movements in the market rate of interest. The Group has \u00a3170,000,000 (2022: \u00a3170,000,000) of committed term loans and revolving credit facilities which were charged interest at a rate of SONIA plus the relevant margin. At the year-end \u00a380,000,000 of the variable rate facilities had been drawn down (2022: \u00a384,750,000). The fair value of the variable rate borrowings is affected by changes in the market rate of the lending margin that would apply to similar loans. The variable rate borrowings are carried at amortised cost and the Group considers this to be a close approximation to fair value at 30 June 2023 and 30 June 2022. At 30 June 2023, the Group had fully hedged its exposure on the \u00a380,000,000 of drawn variable rate borrowings (2022: \u00a354,750,000 of the \u00a384,750,000 of variable rate facilities was unhedged). On any unhedged variable rate borrowings, interest is payable at a variable rate equal  to SONIA plus the weighted average lending margin, including the amortisation of costs, of 2.46 per cent per annum (2022: 2.43 per cent). The variable rate borrowings expose the Group to cash flow interest rate risk as the Group\u2019s income and operating cash flows will be affected by movements in the market rate of interest. The Group has fixed rate term loans totalling \u00a3150,000,000 (2022: \u00a3150,000,000) and has hedged its exposure to increases in interest rates on \u00a380,000,000 (2022: \u00a330,000,000) of the variable rate loans, as referred to above, through entering into a \u00a330,000,000 fixed rate interest rate swap and a \u00a350,000,000 interest rate cap at 3.0%. Fixing the interest rate exposes the Group to fair value interest rate risk as the fair value of the fixed rate borrowings, or the fair value of the interest rate derivative used to fix the interest rate on an otherwise variable rate loan, will be affected by movements in the market rate of interest. The \u00a3150,000,000 fixed rate term loans are carried at amortised cost on the Group\u2019s balance sheet, with the estimated fair value and cost of repayment being disclosed in Note 13, whereas the fair value of the interest rate derivatives are recognised directly on the Group\u2019s balance sheet. At 30 June 2023, an increase of 0.25 per cent in interest rates would have increased the fair value of the interest rate derivative assets and increased the reported total comprehensive income for the year by \u00a3377,000 (2022: \u00a3211,000). The same movement in interest rates would have decreased the fair value of the fixed rate term loans by an aggregate of \u00a32,169,000 (2022: \u00a32,822,000); however, as the fixed rate loan is held at amortised cost, the reported total comprehensive income for the year would have remained unchanged. A decrease in interest rates would have had an approximately equal and opposite effect. Further details on the Group\u2019s borrowings are detailed in Note 13. The following table sets out the carrying amount of the Group\u2019s financial instruments that are exposed to interest rate risk: As at 30 June 2023 As at 30 June 2022 Fixed rate \u00a3\u2019000 Variable rate \u00a3\u2019000 Fixed rate \u00a3\u2019000 Variable rate \u00a3\u2019000 Cash and cash equivalents \u2013 15,366 \u2013 34,483 Loans (230,000) \u2013 (180,000) (54,750) (230,000) 15,366 (180,000) (20,267) Based on the Group\u2019s exposure to cash flow interest rate risk, an increase of 0.25 per cent in interest rates would have increased the reported profit for the year and the net assets at the year end by \u00a338,000 (2022: decrease of \u00a351,000), a decrease in interest rates would have an equal and opposite effect. These movements are calculated based on balances as at 30 June 2023 (30 June 2022) and may not be reflective of actual future conditions. Market price risk The management of market price risk is part of the investment management process and is typical of a property investment company. The portfolio is managed with an awareness of the effects of adverse valuation movements through detailed and continuing analysis, with an objective of maximising overall returns to shareholders. Investments in property and property-related assets are inherently difficult to value due to the individual nature of each property. As a result, valuations are subject to substantial uncertainty. There is no assurance that the estimates resulting from the valuation process will reflect the actual sales price even where such sales occur shortly after the valuation date. Such risk is minimised through the appointment of external property valuers. The basis of valuation of the property portfolio is set out in detail in the accounting policies and Note 9. As set out in Note 9, Colliers are mindful of the potential impacts ESG may have on capital and rental valuations. Currently in the UK, the external valuers have not seen consistent prima facie evidence to suggest that ESG has a direct impact on the valuation of all commercial and residential buildings. However, as the UK real estate market continues to adapt to ESG development practices and legislative requirements, Colliers anticipate  an evolution in the analysis undertaken when providing real estate valuations. This may potentially impact on the valuation of a property over the course of a typical investment period. Any changes in market conditions will directly affect the profit and loss reported through the Statement of Comprehensive Income. Details of the Group\u2019s investment property portfolio held at the balance sheet date are disclosed in Note 9. A 10 per cent increase in the carrying value of the investment properties as at 30 June 2023 (30 June 2022) would have increased net assets available to shareholders and increased the net income for the year by \u00a380,016,000 (2022: \u00a385,769,000); an equal and opposite movement would have decreased net assets and decreased the net income by an equivalent amount. The calculations are based on the investment property valuations at the respective balance sheet date and may not be reflective of future market conditions.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-353": {
   "value": "16. Financial instruments Consistent with its objective, the Group holds UK care home property investments. In addition, the Group\u2019s financial instruments comprise cash, loans and receivables and payables that arise directly from its operations. The Group\u2019s exposure to derivative instruments consists of interest rate swaps and interest rate caps used to fix the interest rate on the Group\u2019s variable rate borrowings. The Group is exposed to various types of risk that are associated with financial instruments. The most important types are credit risk,  liquidity risk, interest rate risk and market price risk. There is no foreign currency risk as all assets and liabilities of the Group are maintained  in pounds sterling. The Board reviews and agrees policies for managing the Group\u2019s risk exposure. These policies are summarised below and have remained unchanged for the year under review. These disclosures include, where appropriate, consideration of the Group\u2019s investment properties which, whilst not constituting financial instruments as defined by IFRS, are considered by the Board to be integral to the Group\u2019s overall risk exposure. Credit risk Credit risk is the risk that an issuer or counterparty will be unable or unwilling to meet a commitment that it has entered into with the Group.  At the reporting date, the Group\u2019s financial assets exposed to credit risk amounted to \u00a323,517,000 (2022: \u00a338,996,000), consisting of cash  of \u00a315,366,000 (2022: \u00a334,483,000), cash held in escrow for property purchases of \u00a34,295,000 (2022: \u00a3nil), net rent receivable of \u00a31,088,000 (2022: \u00a3906,000), VAT recoverable of \u00a3667,000 (2022: \u00a31,387,000), accrued development interest of \u00a31,010,000 (2022: \u00a3452,000) and other debtors of \u00a31,091,000 (2022: \u00a31,768,000). In the event of default by a tenant if it is in financial difficulty or otherwise unable to meet its obligations under the lease, the Group will  suffer a rental shortfall and incur additional expenses until the property is relet. These expenses could include legal and surveyor\u2019s costs in reletting, maintenance costs, insurances, rates and marketing costs and may have a material adverse impact on the financial condition and performance of the Group and/or the level of dividend cover. The Group may also require to provide rental incentives to the incoming tenant. The Board receives regular reports on concentrations of risk and any tenants in arrears. The Investment Manager monitors such reports in order to anticipate, and minimise the impact of, defaults by occupational tenants. The expected credit risk in relation to tenants is an inherent element of the due diligence considered by the Investment Manager on all property transactions with an emphasis being placed on ensuring that initial rents are set at a sustainable level. The risk is further mitigated by rental deposits or guarantees where considered appropriate. The majority of rental income is received in advance. As at 30 June 2023, the Group had recognised a credit loss allowance totalling \u00a31,972,000 against a gross rent receivable balance of \u00a32,496,000 and gross loans to tenants totalling \u00a3989,000. As at 30 June 2022, the gross receivable was \u00a38,496,000, of which \u00a31,280,000 was subsequently recovered, \u00a35,117,000 was written off and \u00a32,099,000 is still outstanding. There were no other financial assets which were either past due or considered impaired at 30 June 2023 (2022: nil). All of the Group\u2019s cash is placed with financial institutions with a long-term credit rating of BBB or better. Bankruptcy or insolvency of such financial institutions may cause the Group\u2019s ability to access cash placed on deposit to be delayed, limited or lost. Should the credit quality  or the financial position of the banks currently employed significantly deteriorate, cash holdings would be moved to another bank. Should the Group hold significant cash balances for an extended period, then counterparty risk will be spread, by placing cash across different financial institutions. At 30 June 2023 the Group held \u00a315.2 million (2022: \u00a334.5 million) with The Royal Bank of Scotland plc and \u00a30.2 million (2022: \u00a3nil) with HSBC Bank plc. Given the credit quality of the counterparties used, no credit loss allowance is recognised against cash balances as it is considered to be immaterial. Liquidity risk Liquidity risk is the risk that the Group will encounter difficulties in realising assets or otherwise raising funds to meet financial commitments. The Group\u2019s investments comprise UK care homes. Property and property-related assets in which the Group invests are not traded in an organised public market and may be illiquid. As a result, the Group may not be able to liquidate quickly its investments in these properties  at an amount close to their fair value in order to meet its liquidity requirements. The Group\u2019s liquidity risk is managed on an on-going basis by the Investment Manager and monitored on a quarterly basis by the Board.  In order to mitigate liquidity risk the Group aims to have sufficient cash balances (including the expected proceeds of any property sales)  to meet its obligations for a period of at least twelve months. At the reporting date, the maturity of the financial assets was: Financial assets as at 30 June 2023 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Cash 15,366 \u2013 \u2013 \u2013 \u2013 15,366 Rental deposits held in escrow for tenants \u2013 \u2013 \u2013 \u2013 8,093 8,093 Cash held in escrow for property purchases 4,295 \u2013 \u2013 \u2013 \u2013 4,295 Other debtors 3,856 \u2013 \u2013 \u2013 \u2013 3,856 Total 23,517 \u2013 \u2013 \u2013 8,093 31,610 Financial assets as at 30 June 2022 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Cash 34,483 \u2013 \u2013 \u2013 \u2013 34,483 Rental deposits held in escrow for tenants \u2013 \u2013 \u2013 \u2013 7,145 7,145 Other debtors 4,513 \u2013 \u2013 \u2013 \u2013 4,513 Total 38,996 \u2013 \u2013 \u2013 7,145 46,141 At the reporting date, the maturity of the financial liabilities was: Financial liabilities as at 30 June 2023 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Loans and interest rate derivatives 2,269 6,757 9,001 95,821 176,747 290,595 Rental deposits \u2013 \u2013 \u2013 \u2013 8,093 8,093 Other payables 10,067 \u2013 \u2013 \u2013 \u2013 10,067 Total 12,336 6,757 9,001 95,821 184,840 308,755 Financial liabilities as at 30 June 2022 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Loans and interest rate derivatives 2,046 6,072 8,140 101,890 181,533 299,681 Rental deposits \u2013 \u2013 \u2013 \u2013 7,145 7,145 Other payables 17,973 \u2013 \u2013 \u2013 \u2013 17,973 Total 20,019 6,072 8,140 101,890 188,678 324,799 The total amount due under the loan facilities includes the expected hedged interest payments due under both the loan and interest rate derivatives combined (see Note 13 for further details) assuming that both the drawn element of the loans and the notional value of the interest rate derivatives remain unchanged from 30 June 2023 (30 June 2022) until the repayment date of the relevant loan and expiry date of the related interest rate derivative. The interest rate on any unhedged element of the loans is based on the rate of SONIA at 30 June 2023 (30 June 2022) plus the relevant lending margin. The commitment fee payable on the undrawn element of any facility is included, where applicable . Interest rate risk Some of the Company\u2019s financial instruments are interest-bearing. Interest-rate risk is the risk that future cash flows will change adversely  as a result of changes in market interest rates. The Group\u2019s policy is to hold cash in variable rate or short-term fixed rate bank accounts. At 30 June 2023, interest was being received on cash at a weighted average variable rate of nil (2022: nil). Exposure varies throughout the period as a consequence of changes in the composition of the net assets of the Group arising out of the investment and risk management policies. These balances expose the Group to cash flow interest rate risk as the Group\u2019s income and operating cash flows will be affected by movements in the market rate of interest. The Group has \u00a3170,000,000 (2022: \u00a3170,000,000) of committed term loans and revolving credit facilities which were charged interest at a rate of SONIA plus the relevant margin. At the year-end \u00a380,000,000 of the variable rate facilities had been drawn down (2022: \u00a384,750,000). The fair value of the variable rate borrowings is affected by changes in the market rate of the lending margin that would apply to similar loans. The variable rate borrowings are carried at amortised cost and the Group considers this to be a close approximation to fair value at 30 June 2023 and 30 June 2022. At 30 June 2023, the Group had fully hedged its exposure on the \u00a380,000,000 of drawn variable rate borrowings (2022: \u00a354,750,000 of the \u00a384,750,000 of variable rate facilities was unhedged). On any unhedged variable rate borrowings, interest is payable at a variable rate equal  to SONIA plus the weighted average lending margin, including the amortisation of costs, of 2.46 per cent per annum (2022: 2.43 per cent). The variable rate borrowings expose the Group to cash flow interest rate risk as the Group\u2019s income and operating cash flows will be affected by movements in the market rate of interest. The Group has fixed rate term loans totalling \u00a3150,000,000 (2022: \u00a3150,000,000) and has hedged its exposure to increases in interest rates on \u00a380,000,000 (2022: \u00a330,000,000) of the variable rate loans, as referred to above, through entering into a \u00a330,000,000 fixed rate interest rate swap and a \u00a350,000,000 interest rate cap at 3.0%. Fixing the interest rate exposes the Group to fair value interest rate risk as the fair value of the fixed rate borrowings, or the fair value of the interest rate derivative used to fix the interest rate on an otherwise variable rate loan, will be affected by movements in the market rate of interest. The \u00a3150,000,000 fixed rate term loans are carried at amortised cost on the Group\u2019s balance sheet, with the estimated fair value and cost of repayment being disclosed in Note 13, whereas the fair value of the interest rate derivatives are recognised directly on the Group\u2019s balance sheet. At 30 June 2023, an increase of 0.25 per cent in interest rates would have increased the fair value of the interest rate derivative assets and increased the reported total comprehensive income for the year by \u00a3377,000 (2022: \u00a3211,000). The same movement in interest rates would have decreased the fair value of the fixed rate term loans by an aggregate of \u00a32,169,000 (2022: \u00a32,822,000); however, as the fixed rate loan is held at amortised cost, the reported total comprehensive income for the year would have remained unchanged. A decrease in interest rates would have had an approximately equal and opposite effect. Further details on the Group\u2019s borrowings are detailed in Note 13. The following table sets out the carrying amount of the Group\u2019s financial instruments that are exposed to interest rate risk: As at 30 June 2023 As at 30 June 2022 Fixed rate \u00a3\u2019000 Variable rate \u00a3\u2019000 Fixed rate \u00a3\u2019000 Variable rate \u00a3\u2019000 Cash and cash equivalents \u2013 15,366 \u2013 34,483 Loans (230,000) \u2013 (180,000) (54,750) (230,000) 15,366 (180,000) (20,267) Based on the Group\u2019s exposure to cash flow interest rate risk, an increase of 0.25 per cent in interest rates would have increased the reported profit for the year and the net assets at the year end by \u00a338,000 (2022: decrease of \u00a351,000), a decrease in interest rates would have an equal and opposite effect. These movements are calculated based on balances as at 30 June 2023 (30 June 2022) and may not be reflective of actual future conditions. Market price risk The management of market price risk is part of the investment management process and is typical of a property investment company. The portfolio is managed with an awareness of the effects of adverse valuation movements through detailed and continuing analysis, with an objective of maximising overall returns to shareholders. Investments in property and property-related assets are inherently difficult to value due to the individual nature of each property. As a result, valuations are subject to substantial uncertainty. There is no assurance that the estimates resulting from the valuation process will reflect the actual sales price even where such sales occur shortly after the valuation date. Such risk is minimised through the appointment of external property valuers. The basis of valuation of the property portfolio is set out in detail in the accounting policies and Note 9. As set out in Note 9, Colliers are mindful of the potential impacts ESG may have on capital and rental valuations. Currently in the UK, the external valuers have not seen consistent prima facie evidence to suggest that ESG has a direct impact on the valuation of all commercial and residential buildings. However, as the UK real estate market continues to adapt to ESG development practices and legislative requirements, Colliers anticipate  an evolution in the analysis undertaken when providing real estate valuations. This may potentially impact on the valuation of a property over the course of a typical investment period. Any changes in market conditions will directly affect the profit and loss reported through the Statement of Comprehensive Income. Details of the Group\u2019s investment property portfolio held at the balance sheet date are disclosed in Note 9. A 10 per cent increase in the carrying value of the investment properties as at 30 June 2023 (30 June 2022) would have increased net assets available to shareholders and increased the net income for the year by \u00a380,016,000 (2022: \u00a385,769,000); an equal and opposite movement would have decreased net assets and decreased the net income by an equivalent amount. The calculations are based on the investment property valuations at the respective balance sheet date and may not be reflective of future market conditions.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-374": {
   "value": "Credit risk Credit risk is the risk that an issuer or counterparty will be unable or unwilling to meet a commitment that it has entered into with the Group.  At the reporting date, the Group\u2019s financial assets exposed to credit risk amounted to \u00a323,517,000 (2022: \u00a338,996,000), consisting of cash  of \u00a315,366,000 (2022: \u00a334,483,000), cash held in escrow for property purchases of \u00a34,295,000 (2022: \u00a3nil), net rent receivable of \u00a31,088,000 (2022: \u00a3906,000), VAT recoverable of \u00a3667,000 (2022: \u00a31,387,000), accrued development interest of \u00a31,010,000 (2022: \u00a3452,000) and other debtors of \u00a31,091,000 (2022: \u00a31,768,000). In the event of default by a tenant if it is in financial difficulty or otherwise unable to meet its obligations under the lease, the Group will  suffer a rental shortfall and incur additional expenses until the property is relet. These expenses could include legal and surveyor\u2019s costs in reletting, maintenance costs, insurances, rates and marketing costs and may have a material adverse impact on the financial condition and performance of the Group and/or the level of dividend cover. The Group may also require to provide rental incentives to the incoming tenant. The Board receives regular reports on concentrations of risk and any tenants in arrears. The Investment Manager monitors such reports in order to anticipate, and minimise the impact of, defaults by occupational tenants. The expected credit risk in relation to tenants is an inherent element of the due diligence considered by the Investment Manager on all property transactions with an emphasis being placed on ensuring that initial rents are set at a sustainable level. The risk is further mitigated by rental deposits or guarantees where considered appropriate. The majority of rental income is received in advance. As at 30 June 2023, the Group had recognised a credit loss allowance totalling \u00a31,972,000 against a gross rent receivable balance of \u00a32,496,000 and gross loans to tenants totalling \u00a3989,000. As at 30 June 2022, the gross receivable was \u00a38,496,000, of which \u00a31,280,000 was subsequently recovered, \u00a35,117,000 was written off and \u00a32,099,000 is still outstanding. There were no other financial assets which were either past due or considered impaired at 30 June 2023 (2022: nil). All of the Group\u2019s cash is placed with financial institutions with a long-term credit rating of BBB or better. Bankruptcy or insolvency of such financial institutions may cause the Group\u2019s ability to access cash placed on deposit to be delayed, limited or lost. Should the credit quality  or the financial position of the banks currently employed significantly deteriorate, cash holdings would be moved to another bank. Should the Group hold significant cash balances for an extended period, then counterparty risk will be spread, by placing cash across different financial institutions. At 30 June 2023 the Group held \u00a315.2 million (2022: \u00a334.5 million) with The Royal Bank of Scotland plc and \u00a30.2 million (2022: \u00a3nil) with HSBC Bank plc. Given the credit quality of the counterparties used, no credit loss allowance is recognised against cash balances as it is considered to be immaterial. ",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfCreditRiskExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-375": {
   "value": "Liquidity risk Liquidity risk is the risk that the Group will encounter difficulties in realising assets or otherwise raising funds to meet financial commitments. The Group\u2019s investments comprise UK care homes. Property and property-related assets in which the Group invests are not traded in an organised public market and may be illiquid. As a result, the Group may not be able to liquidate quickly its investments in these properties  at an amount close to their fair value in order to meet its liquidity requirements. The Group\u2019s liquidity risk is managed on an on-going basis by the Investment Manager and monitored on a quarterly basis by the Board.  In order to mitigate liquidity risk the Group aims to have sufficient cash balances (including the expected proceeds of any property sales)  to meet its obligations for a period of at least twelve months. At the reporting date, the maturity of the financial assets was: Financial assets as at 30 June 2023 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Cash 15,366 \u2013 \u2013 \u2013 \u2013 15,366 Rental deposits held in escrow for tenants \u2013 \u2013 \u2013 \u2013 8,093 8,093 Cash held in escrow for property purchases 4,295 \u2013 \u2013 \u2013 \u2013 4,295 Other debtors 3,856 \u2013 \u2013 \u2013 \u2013 3,856 Total 23,517 \u2013 \u2013 \u2013 8,093 31,610 Financial assets as at 30 June 2022 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Cash 34,483 \u2013 \u2013 \u2013 \u2013 34,483 Rental deposits held in escrow for tenants \u2013 \u2013 \u2013 \u2013 7,145 7,145 Other debtors 4,513 \u2013 \u2013 \u2013 \u2013 4,513 Total 38,996 \u2013 \u2013 \u2013 7,145 46,141 At the reporting date, the maturity of the financial liabilities was: Financial liabilities as at 30 June 2023 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Loans and interest rate derivatives 2,269 6,757 9,001 95,821 176,747 290,595 Rental deposits \u2013 \u2013 \u2013 \u2013 8,093 8,093 Other payables 10,067 \u2013 \u2013 \u2013 \u2013 10,067 Total 12,336 6,757 9,001 95,821 184,840 308,755 Financial liabilities as at 30 June 2022 Three months or less \u00a3\u2019000 More than three months but less than one year \u00a3\u2019000 1-2 years \u00a3\u2019000 2-5 years \u00a3\u2019000 More than  five years \u00a3\u2019000 Total \u00a3\u2019000 Loans and interest rate derivatives 2,046 6,072 8,140 101,890 181,533 299,681 Rental deposits \u2013 \u2013 \u2013 \u2013 7,145 7,145 Other payables 17,973 \u2013 \u2013 \u2013 \u2013 17,973 Total 20,019 6,072 8,140 101,890 188,678 324,799 The total amount due under the loan facilities includes the expected hedged interest payments due under both the loan and interest rate derivatives combined (see Note 13 for further details) assuming that both the drawn element of the loans and the notional value of the interest rate derivatives remain unchanged from 30 June 2023 (30 June 2022) until the repayment date of the relevant loan and expiry date of the related interest rate derivative. The interest rate on any unhedged element of the loans is based on the rate of SONIA at 30 June 2023 (30 June 2022) plus the relevant lending margin. The commitment fee payable on the undrawn element of any facility is included, where applicable ",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfLiquidityRiskExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-376": {
   "value": "Interest rate risk Some of the Company\u2019s financial instruments are interest-bearing. Interest-rate risk is the risk that future cash flows will change adversely  as a result of changes in market interest rates. The Group\u2019s policy is to hold cash in variable rate or short-term fixed rate bank accounts. At 30 June 2023, interest was being received on cash at a weighted average variable rate of nil (2022: nil). Exposure varies throughout the period as a consequence of changes in the composition of the net assets of the Group arising out of the investment and risk management policies. These balances expose the Group to cash flow interest rate risk as the Group\u2019s income and operating cash flows will be affected by movements in the market rate of interest. The Group has \u00a3170,000,000 (2022: \u00a3170,000,000) of committed term loans and revolving credit facilities which were charged interest at a rate of SONIA plus the relevant margin. At the year-end \u00a380,000,000 of the variable rate facilities had been drawn down (2022: \u00a384,750,000). The fair value of the variable rate borrowings is affected by changes in the market rate of the lending margin that would apply to similar loans. The variable rate borrowings are carried at amortised cost and the Group considers this to be a close approximation to fair value at 30 June 2023 and 30 June 2022. At 30 June 2023, the Group had fully hedged its exposure on the \u00a380,000,000 of drawn variable rate borrowings (2022: \u00a354,750,000 of the \u00a384,750,000 of variable rate facilities was unhedged). On any unhedged variable rate borrowings, interest is payable at a variable rate equal  to SONIA plus the weighted average lending margin, including the amortisation of costs, of 2.46 per cent per annum (2022: 2.43 per cent). The variable rate borrowings expose the Group to cash flow interest rate risk as the Group\u2019s income and operating cash flows will be affected by movements in the market rate of interest. The Group has fixed rate term loans totalling \u00a3150,000,000 (2022: \u00a3150,000,000) and has hedged its exposure to increases in interest rates on \u00a380,000,000 (2022: \u00a330,000,000) of the variable rate loans, as referred to above, through entering into a \u00a330,000,000 fixed rate interest rate swap and a \u00a350,000,000 interest rate cap at 3.0%. Fixing the interest rate exposes the Group to fair value interest rate risk as the fair value of the fixed rate borrowings, or the fair value of the interest rate derivative used to fix the interest rate on an otherwise variable rate loan, will be affected by movements in the market rate of interest. The \u00a3150,000,000 fixed rate term loans are carried at amortised cost on the Group\u2019s balance sheet, with the estimated fair value and cost of repayment being disclosed in Note 13, whereas the fair value of the interest rate derivatives are recognised directly on the Group\u2019s balance sheet. At 30 June 2023, an increase of 0.25 per cent in interest rates would have increased the fair value of the interest rate derivative assets and increased the reported total comprehensive income for the year by \u00a3377,000 (2022: \u00a3211,000). The same movement in interest rates would have decreased the fair value of the fixed rate term loans by an aggregate of \u00a32,169,000 (2022: \u00a32,822,000); however, as the fixed rate loan is held at amortised cost, the reported total comprehensive income for the year would have remained unchanged. A decrease in interest rates would have had an approximately equal and opposite effect. Further details on the Group\u2019s borrowings are detailed in Note 13. The following table sets out the carrying amount of the Group\u2019s financial instruments that are exposed to interest rate risk: As at 30 June 2023 As at 30 June 2022 Fixed rate \u00a3\u2019000 Variable rate \u00a3\u2019000 Fixed rate \u00a3\u2019000 Variable rate \u00a3\u2019000 Cash and cash equivalents \u2013 15,366 \u2013 34,483 Loans (230,000) \u2013 (180,000) (54,750) (230,000) 15,366 (180,000) (20,267) Based on the Group\u2019s exposure to cash flow interest rate risk, an increase of 0.25 per cent in interest rates would have increased the reported profit for the year and the net assets at the year end by \u00a338,000 (2022: decrease of \u00a351,000), a decrease in interest rates would have an equal and opposite effect. These movements are calculated based on balances as at 30 June 2023 (30 June 2022) and may not be reflective of actual future conditions. Market price risk The management of market price risk is part of the investment management process and is typical of a property investment company. The portfolio is managed with an awareness of the effects of adverse valuation movements through detailed and continuing analysis, with an objective of maximising overall returns to shareholders. Investments in property and property-related assets are inherently difficult to value due to the individual nature of each property. As a result, valuations are subject to substantial uncertainty. There is no assurance that the estimates resulting from the valuation process will reflect the actual sales price even where such sales occur shortly after the valuation date. Such risk is minimised through the appointment of external property valuers. The basis of valuation of the property portfolio is set out in detail in the accounting policies and Note 9. As set out in Note 9, Colliers are mindful of the potential impacts ESG may have on capital and rental valuations. Currently in the UK, the external valuers have not seen consistent prima facie evidence to suggest that ESG has a direct impact on the valuation of all commercial and residential buildings. However, as the UK real estate market continues to adapt to ESG development practices and legislative requirements, Colliers anticipate  an evolution in the analysis undertaken when providing real estate valuations. This may potentially impact on the valuation of a property over the course of a typical investment period. Any changes in market conditions will directly affect the profit and loss reported through the Statement of Comprehensive Income. Details of the Group\u2019s investment property portfolio held at the balance sheet date are disclosed in Note 9. A 10 per cent increase in the carrying value of the investment properties as at 30 June 2023 (30 June 2022) would have increased net assets available to shareholders and increased the net income for the year by \u00a380,016,000 (2022: \u00a385,769,000); an equal and opposite movement would have decreased net assets and decreased the net income by an equivalent amount. The calculations are based on the investment property valuations at the respective balance sheet date and may not be reflective of future market conditions.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfMarketRiskExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-354": {
   "value": "17. Lease length The Group has entered into commercial property leases on its investment property portfolio. These properties, held under operating leases, are measured under the fair value model as the properties are held to earn rentals. All leases are non-cancellable leases with lease terms remaining of between 14 and 34 years. The minimum lease payments based on the unexpired lessor lease length at the year-end were as follows (based on annual rentals): As at 30 June 2023 \u00a3\u2019000 As at 30 June 2022 \u00a3\u2019000 Less than one year 56,010 54,408 Between one and two years 58,013 56,750 Between two and three years 58,912 57,618 Between three and four years 59,826 58,517 Between four and five years 60,591 59,439 Over five years 1,570,251 1,630,700 Total 1,863,603 1,917,432 The largest single tenant at the year-end accounted for 16.1 per cent (2022: 15.7 per cent) of the current annual rental income. There were  no unoccupied properties at the year-end (2022: none).",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-377": {
   "value": "17. Lease length The Group has entered into commercial property leases on its investment property portfolio. These properties, held under operating leases, are measured under the fair value model as the properties are held to earn rentals. All leases are non-cancellable leases with lease terms remaining of between 14 and 34 years. The minimum lease payments based on the unexpired lessor lease length at the year-end were as follows (based on annual rentals): As at 30 June 2023 \u00a3\u2019000 As at 30 June 2022 \u00a3\u2019000 Less than one year 56,010 54,408 Between one and two years 58,013 56,750 Between two and three years 58,912 57,618 Between three and four years 59,826 58,517 Between four and five years 60,591 59,439 Over five years 1,570,251 1,630,700 Total 1,863,603 1,917,432 The largest single tenant at the year-end accounted for 16.1 per cent (2022: 15.7 per cent) of the current annual rental income. There were  no unoccupied properties at the year-end (2022: none).",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfLeasesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-355": {
   "value": "18. Contingent assets and liabilities As at 30 June 2023, six (2022: fourteen) properties within the Group\u2019s investment property portfolio contained performance payment clauses meaning that, subject to contracted performance conditions being met, further capital payments totalling \u00a35,720,000 (2022: \u00a313,320,000) may be payable by the Group to the vendors/tenants of these properties. The potential timings of these payments are also conditional on  the date(s) at which the contracted performance conditions are met and are therefore uncertain. It is highlighted that any performance payments subsequently paid will result in an increase in the rental income due from the tenant of the relevant property. As the net initial yield used to calculate the additional rental which would be payable is not significantly different from the investment yield used to arrive at the valuation of the properties, any performance payments made would be expected to result in a commensurate increase in the value of the Group\u2019s investment property portfolio. Having assessed each clause on an individual basis, the Group has determined that the contracted performance conditions had not been met in relation to any of these properties and therefore at 30 June 2023 no liability was recognised (2022: \u00a32,800,000). Had a liability been recognised, an equal but opposite amount would have been recognised as an asset in \u2018investment properties\u2019 in Note 9 to reflect the increase in the investment property value that would be expected to arise from the payment of the performance payment(s) and the resulting increase in the contracted rental income. The performance payments of \u00a32,800,000 recognised as a liability at 30 June 2022 were paid during the year ended 30 June 2023 (see Note 9). 19. Capital commitments The Group had capital commitments as follows: 30 June 2023 \u00a3\u2019000 30 June 2022 \u00a3\u2019000 Amounts due to complete forward fund developments 31,066 34,458 Other capital expenditure commitments 2,160 3,594 Total 33,226 38,052",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-378": {
   "value": "18. Contingent assets and liabilities As at 30 June 2023, six (2022: fourteen) properties within the Group\u2019s investment property portfolio contained performance payment clauses meaning that, subject to contracted performance conditions being met, further capital payments totalling \u00a35,720,000 (2022: \u00a313,320,000) may be payable by the Group to the vendors/tenants of these properties. The potential timings of these payments are also conditional on  the date(s) at which the contracted performance conditions are met and are therefore uncertain. It is highlighted that any performance payments subsequently paid will result in an increase in the rental income due from the tenant of the relevant property. As the net initial yield used to calculate the additional rental which would be payable is not significantly different from the investment yield used to arrive at the valuation of the properties, any performance payments made would be expected to result in a commensurate increase in the value of the Group\u2019s investment property portfolio. Having assessed each clause on an individual basis, the Group has determined that the contracted performance conditions had not been met in relation to any of these properties and therefore at 30 June 2023 no liability was recognised (2022: \u00a32,800,000). Had a liability been recognised, an equal but opposite amount would have been recognised as an asset in \u2018investment properties\u2019 in Note 9 to reflect the increase in the investment property value that would be expected to arise from the payment of the performance payment(s) and the resulting increase in the contracted rental income. The performance payments of \u00a32,800,000 recognised as a liability at 30 June 2022 were paid during the year ended 30 June 2023 (see Note 9). ",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-379": {
   "value": "19. Capital commitments The Group had capital commitments as follows: 30 June 2023 \u00a3\u2019000 30 June 2022 \u00a3\u2019000 Amounts due to complete forward fund developments 31,066 34,458 Other capital expenditure commitments 2,160 3,594 Total 33,226 38,052",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfCommitmentsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-356": {
   "value": "20. Related party transactions The Board of Directors is considered to be a related party. No Director has an interest in any transactions which are, or were, unusual in their nature or significant to the nature of the Group. The Directors of the Group received fees for their services. Total fees for the year were \u00a3218,000 (2022: \u00a3214,000) of which \u00a3nil (2022: \u00a3nil) remained payable at the year-end. The Investment Manager received \u00a37,428,000 (inclusive of irrecoverable VAT) in management fees in relation to the year ended 30 June 2023 (2022: \u00a37,307,000). Of this amount \u00a31,835,000 (2022: \u00a31,895,000) remained payable at the year-end. The Investment Manager received a further \u00a3169,000 (inclusive of irrecoverable VAT) during the year ended 30 June 2023 (2022: \u00a3151,000) in relation to its appointment as Company Secretary and Administrator, of which \u00a342,000 (2022: \u00a338,000) remained payable at the year end. Certain employees of the Investment Manager are directors of some of the Group\u2019s subsidiaries. Neither they nor the Investment Manager receive any additional remuneration in relation to fulfilling this role. There were related party transactions within the Group and its wholly-owned subsidiaries which are eliminated upon consolidation.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-380": {
   "value": "20. Related party transactions The Board of Directors is considered to be a related party. No Director has an interest in any transactions which are, or were, unusual in their nature or significant to the nature of the Group. The Directors of the Group received fees for their services. Total fees for the year were \u00a3218,000 (2022: \u00a3214,000) of which \u00a3nil (2022: \u00a3nil) remained payable at the year-end. The Investment Manager received \u00a37,428,000 (inclusive of irrecoverable VAT) in management fees in relation to the year ended 30 June 2023 (2022: \u00a37,307,000). Of this amount \u00a31,835,000 (2022: \u00a31,895,000) remained payable at the year-end. The Investment Manager received a further \u00a3169,000 (inclusive of irrecoverable VAT) during the year ended 30 June 2023 (2022: \u00a3151,000) in relation to its appointment as Company Secretary and Administrator, of which \u00a342,000 (2022: \u00a338,000) remained payable at the year end. Certain employees of the Investment Manager are directors of some of the Group\u2019s subsidiaries. Neither they nor the Investment Manager receive any additional remuneration in relation to fulfilling this role. There were related party transactions within the Group and its wholly-owned subsidiaries which are eliminated upon consolidation",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-357": {
   "value": "21. Operating segments The Board has considered the requirements of IFRS 8 \u2018Operating Segments\u2019. The Board is of the view that the Group is engaged in a single segment of business, being property investment, and in one geographical area, the United Kingdom, and that therefore the Group has only  a single operating segment. The Board of Directors, as a whole, has been identified as constituting the chief operating decision maker of the Group. The key measure of performance used by the Board to assess the Group\u2019s performance is the EPRA NTA. The reconciliation between the NAV, as calculated under IFRS, and the EPRA NTA is detailed in Note 8. The view that the Group is engaged in a single segment of business is based on the following considerations: \u2013 One of the key financial indicators received and reviewed by the Board is the total return from the property portfolio taken as a whole; \u2013 There is no active allocation of resources to particular types or groups of properties in order to try to match the asset allocation of the benchmark; and \u2013 The management of the portfolio is ultimately delegated to a single property manager, Target.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-358": {
   "value": "22. Post balance sheet events Subsequent to the year end, the Group acquired a pre-let development site subject to a forward funding agreement to construct a 66-bed care home in Weston-super-Mare, Somerset for a maximum commitment of \u00a316.0 million including acquisition costs. Construction on the home has commenced and is expected to be completed in the summer of 2024.",
   "dimensions": {
    "concept": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-359": {
   "value": "23. Alternative Investment Fund Managers (\u2018AIFM\u2019) Directive With effect from 22 July 2014, the Company\u2019s Investment Manager was authorised as an AIFM by the FCA under the AIFMD regulations.  In accordance with the AIFM Directive, information in relation to the Group\u2019s leverage and the remuneration of the Company\u2019s AIFM, Target Fund Managers Limited, is required to be made available to investors. The Manager has provided disclosures on its website,  www.targetfundmanagers.com, incorporating the requirements of the AIFMD regulations regarding remuneration. The Group\u2019s maximum and average actual leverage levels at 30 June 2023 are shown below: Leverage exposure Gross method Commitment method Maximum limit 3.00 3.00 Actual 1.82 1.84 For the purposes of the AIFM Directive, leverage is any method which increases the Group\u2019s exposure, including the borrowing of cash and  the use of derivatives. It is expressed as a percentage of the Group\u2019s exposure to its net asset value and is calculated on both a gross and commitment method. Under the gross method, exposure represents the sum of the Group\u2019s positions after deduction of cash balances, without taking account of any hedging or netting arrangements. Under the commitment method, exposure is calculated without the deduction of cash balances and after certain hedging and netting positions are offset against each other. Both methods include the Group\u2019s interest rate derivatives measured at notional value. The leverage limits are set by the AIFM and approved by the Board and are in line with the maximum leverage levels permitted in the Company\u2019s Articles of Association. The AIFM is also required to comply with the gearing parameters set by the Board in relation to borrowings. Detailed regulatory disclosures to investors in accordance with the AIFM Directive are contained in the Investor Disclosure Document which  is made available on the Group\u2019s website at www.targethealthcarereit.co.uk",
   "dimensions": {
    "concept": "targethealthcare:DisclosureOfAlternativeInvestmentFundManagersAIFMDirective",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  },
  "fact-360": {
   "value": "Level 4 Dashwood House 69 Old Broad Street London EC2M 1QS",
   "dimensions": {
    "concept": "ifrs-full:AddressOfRegisteredOfficeOfEntity",
    "language": "en",
    "entity": "scheme:213800RXPY9WULUSBC04",
    "period": "2022-07-01T00:00:00/2023-07-01T00:00:00"
   }
  }
 }
}